Background	Background	NN	0
The	The	DT	0
ligand	ligand	NN	B-NP
cysteine-loop	cysteine-loop	JJ	I-NP
family	family	NN	I-NP
gated	gated	FW	0
ion	ion	FW	0
channels	channels	FW	0
(	(	-LRB-	0
ligand	ligand	NN	B-NP
gated	gated	VBN	I-NP
ion	ion	NN	I-NP
channel	channel	NN	I-NP
)	)	-RRB-	0
is	is	VBZ	0
comprised	comprised	VBN	0
of	of	IN	0
receptor	receptor	NN	B-NP
with	with	IN	0
pentameric	pentameric	JJ	B-NP
quaternary	quaternary	JJ	I-NP
structure	structure	NN	I-NP
and	and	CC	0
at	at	IN	0
least	least	JJS	0
two	two	CD	0
ligand	ligand	CD	B-NP
binding	binding	JJ	0
sites	sites	NNS	0
present	present	JJ	0
at	at	IN	0
the	the	DT	0
subunit	subunit	JJ	B-NP
interface	interface	NN	I-NP
[	[	-LRB-	0
1	1	CD	0
2	2	CD	0
]	]	-RRB-	0
.	.	.	0
This	This	DT	0
receptor	receptor	NN	B-NP
family	family	NN	I-NP
is	is	VBZ	0
characterized	characterized	VBN	0
by	by	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
a	a	DT	0
critical	critical	JJ	B-NP
disulfide	disulfide	JJ	I-NP
loop	loop	JJ	I-NP
structure	structure	NN	I-NP
within	within	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
and	and	CC	0
an	an	DT	0
selective	selective	JJ	B-NP
channel	channel	NN	I-NP
integral	integral	JJ	I-NP
ion	ion	JJ	I-NP
.	.	.	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
are	are	VBP	0
found	found	VBN	0
in	in	IN	0
both	both	PDT	0
the	the	DT	0
peripheral	peripheral	JJ	0
and	and	CC	0
central	central	JJ	0
nervous	nervous	JJ	0
systems	systems	NNS	0
.	.	.	0
Members	Members	NNS	0
of	of	IN	0
this	this	DT	0
family	family	NN	0
include	include	VBP	0
the	the	DT	0
acetylcholine	acetylcholine	JJ	B-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
3	3	CD	0
4	4	CD	0
]	]	-RRB-	0
,	,	,	0
the	the	DT	0
γ-amino	γ-amino	JJ	B-NP
butyric	butyric	JJ	I-NP
acid	acid	NN	I-NP
type	type	NN	I-NP
A	A	DT	0
receptor	receptor	NN	B-NP
(	(	-LRB-	0
γ-amino	γ-amino	NN	B-NP
butyric	butyric	NN	I-NP
acid	acid	JJ	I-NP
type	type	NN	I-NP
a	a	DT	I-NP
A	A	NNP	0
R	R	NNP	0
)	)	-RRB-	0
[	[	-LRB-	0
5	5	LS	0
]	]	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
glycine	glycine	JJ	B-NP
receptor	receptor	NN	I-NP
(	(	-LRB-	0
GlyR	GlyR	NNP	B-NP
)	)	-RRB-	0
[	[	-LRB-	0
6	6	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
first	first	JJ	0
subunit	subunit	NN	B-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
was	was	VBD	0
cloned	cloned	VBN	0
in	in	IN	0
1991	1991	CD	0
[	[	-LRB-	0
7	7	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
sequence	sequence	NN	0
of	of	IN	0
this	this	DT	0
subunit	subunit	NN	B-NP
was	was	VBD	0
shown	shown	VBN	0
to	to	TO	0
be	be	VB	0
highly	highly	RB	0
homologous	homologous	VBN	0
to	to	TO	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
and	and	CC	0
thus	thus	RB	0
identified	identified	VBN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	B-NP
receptor	receptor	NN	I-NP
as	as	IN	0
another	another	DT	0
member	member	NN	0
of	of	IN	0
this	this	DT	0
superfamily	superfamily	NN	0
[	[	-LRB-	0
7	7	CD	0
8	8	CD	0
9	9	CD	0
]	]	-RRB-	0
.	.	.	0
Similar	Similar	JJ	0
to	to	TO	0
other	other	JJ	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
,	,	,	0
more	more	JJR	0
than	than	IN	0
one	one	CD	0
subtype	subtype	NN	B-NP
has	has	VBZ	0
been	been	VBN	0
identified	identified	VBN	0
.	.	.	0
Two	Two	CD	0
splice	splice	JJ	0
variants	variants	NN	0
of	of	IN	0
an	an	DT	0
A	A	DT	0
subunit	subunit	NN	B-NP
(	(	-LRB-	0
long	long	JJ	0
and	and	CC	0
short	short	JJ	0
forms	forms	NNS	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
a	a	DT	0
single	single	JJ	0
B	B	NN	B-NP
subunit	subunit	NN	I-NP
have	have	VBP	0
been	been	VBN	0
cloned	cloned	NNS	0
[	[	-LRB-	0
10	10	CD	0
11	11	CD	0
12	12	CD	0
13	13	CD	0
]	]	-RRB-	0
.	.	.	0
Both	Both	PDT	0
the	the	DT	0
long	long	JJ	0
and	and	CC	0
short	short	JJ	0
forms	forms	NNS	0
of	of	IN	0
the	the	DT	0
A	A	NN	0
subunit	subunit	NN	B-NP
are	are	VBP	0
capable	capable	JJ	0
of	of	IN	0
forming	forming	FW	0
functional	functional	JJ	B-NP
homomeric	homomeric	NN	I-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
5-HT	5-HT	NNP	0
3AL	3AL	NNP	0
R	R	NNP	0
and	and	CC	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
R	R	NNP	0
]	]	-RRB-	0
although	although	IN	0
some	some	DT	0
differences	differences	NNS	0
between	between	IN	0
an	an	DT	0
agonist	agonist	NN	B-NP
and	and	CC	0
partial	partial	JJ	0
agonist	agonist	JJ	B-NP
activity	activity	NN	I-NP
have	have	VBP	0
been	been	VBN	0
observed	observed	VBN	0
[	[	-LRB-	0
14	14	CD	0
]	]	-RRB-	0
.	.	.	0
A	A	DT	0
third	third	JJ	0
subtype	subtype	NN	B-NP
is	is	VBZ	0
formed	formed	VBN	0
by	by	IN	0
a	a	DT	0
combination	combination	NN	0
of	of	IN	0
the	the	DT	0
A	A	NNP	0
and	and	CC	0
B	B	NNP	0
subunits	subunits	VBD	0
to	to	TO	0
produce	produce	VB	0
a	a	DT	0
heteromeric	heteromeric	JJ	B-NP
receptor	receptor	NN	I-NP
of	of	IN	0
unknown	unknown	JJ	0
stoichiometry	stoichiometry	NN	B-NP
[	[	-LRB-	0
10	10	CD	0
]	]	-RRB-	0
.	.	.	0
heteromeric	heteromeric	NN	B-NP
receptor	receptor	NN	I-NP
are	are	VBP	0
pharmacologically	pharmacologically	VBN	0
and	and	CC	0
functionally	functionally	JJ	0
distinct	distinct	NN	0
from	from	IN	0
the	the	DT	0
homomeric	homomeric	JJ	0
5-HT	5-HT	NNP	0
3AL	3AL	NNP	0
and	and	CC	0
5-HT	5-HT	CD	0
3AS	3AS	CD	0
receptors	receptors	NNS	0
[	[	-LRB-	0
11	11	CD	0
]	]	-RRB-	0
.	.	.	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
are	are	VBP	0
distributed	distributed	VBN	0
throughout	throughout	IN	0
the	the	DT	0
central	central	JJ	0
and	and	CC	0
peripheral	peripheral	JJ	0
nervous	nervous	JJ	0
system	system	NN	0
,	,	,	0
playing	playing	VBG	0
a	a	DT	0
significant	significant	JJ	0
role	role	NN	0
in	in	IN	0
phenomenon	phenomenon	NN	0
such	such	JJ	0
as	as	IN	0
anxiety	anxiety	NN	B-NP
,	,	,	0
emesi	emesi	NN	B-NP
and	and	CC	0
alcoholism	alcoholism	NN	0
.	.	.	0
Antagonists	Antagonists	NNS	0
to	to	TO	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
are	are	VBP	0
clinically	clinically	RB	0
efficacious	efficacious	VBN	0
in	in	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
chemotherapy-induced	chemotherapy-induced	JJ	0
emesi	emesi	NN	B-NP
[	[	-LRB-	0
15	15	CD	0
]	]	-RRB-	0
and	and	CC	0
recent	recent	JJ	0
studies	studies	NNS	0
on	on	IN	0
human	human	JJ	0
subject	subject	JJ	B-NP
have	have	VBP	0
suggested	suggested	VBN	0
their	their	PRP$	0
potential	potential	JJ	B-NP
application	application	NN	I-NP
in	in	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
early	early	JJ	0
onset	onset	NN	B-NP
alcoholism	alcoholism	NN	I-NP
[	[	-LRB-	0
16	16	CD	0
17	17	CD	0
]	]	-RRB-	0
.	.	.	0
Hibert	Hibert	FW	0
et	et	FW	0
al	al	FW	0
proposed	proposed	VBN	0
an	an	DT	0
early	early	JJ	0
model	model	NN	0
for	for	IN	0
the	the	DT	0
antagonist	antagonist	JJ	B-NP
pharmacophore	pharmacophore	NN	I-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
[	[	-LRB-	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
According	According	VBG	0
to	to	TO	0
this	this	DT	0
model	model	NN	0
,	,	,	0
all	all	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
antagonist	antagonist	NN	I-NP
contain	contain	VBP	0
an	an	DT	0
aromatic	aromatic	JJ	B-NP
ring	ring	NN	I-NP
,	,	,	0
a	a	DT	0
carbonyl	carbonyl	JJ	B-NP
oxygen	oxygen	NN	I-NP
or	or	CC	0
bioisosteric	bioisosteric	JJ	B-NP
equivalent	equivalent	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
basic	basic	JJ	0
nitrogen	nitrogen	NN	B-NP
.	.	.	0
According	According	VBG	0
to	to	TO	0
Hibert	Hibert	NNP	0
's	's	POS	0
model	model	NN	0
,	,	,	0
the	the	DT	0
basic	basic	JJ	0
nitrogen	nitrogen	NN	B-NP
is	is	VBZ	0
located	located	VBN	0
5.2A°	5.2A°	CD	0
from	from	IN	0
the	the	DT	0
centre	centre	NN	0
of	of	IN	0
the	the	DT	0
aromatic	aromatic	JJ	B-NP
ring	ring	NN	I-NP
and	and	CC	0
approximately	approximately	RB	0
1.7A°	1.7A°	CD	0
above	above	IN	0
plane	plane	NN	0
of	of	IN	0
the	the	DT	0
ring	ring	NN	0
.	.	.	0
The	The	DT	0
carbonyl	carbonyl	JJ	B-NP
oxygen	oxygen	NN	I-NP
and	and	CC	0
the	the	DT	0
aromatic	aromatic	JJ	B-NP
ring	ring	NN	I-NP
are	are	VBP	0
coplanar	coplanar	VBN	0
and	and	CC	0
separated	separated	VBN	0
by	by	IN	0
a	a	DT	0
distance	distance	NN	0
of	of	IN	0
3.3A°	3.3A°	CD	0
.	.	.	0
recent	recent	JJ	B-NP
study	study	NN	I-NP
have	have	VBP	0
expanded	expanded	VBN	0
on	on	IN	0
this	this	DT	0
model	model	NN	0
to	to	TO	0
include	include	VB	0
another	another	DT	0
lipophilic	lipophilic	JJ	B-NP
region	region	NN	I-NP
and	and	CC	0
a	a	DT	0
second	second	JJ	0
bonding	bonding	VBD	B-NP
interaction	interaction	CD	I-NP
hydrogen	hydrogen	NN	I-NP
two	two	CD	0
atoms	atoms	NNS	0
away	away	RB	0
from	from	IN	0
the	the	DT	0
first	first	JJ	0
[	[	-LRB-	0
19	19	CD	0
20	20	CD	0
21	21	CD	0
]	]	-RRB-	0
.	.	.	0
A	A	DT	0
compound	compound	NN	B-NP
that	that	WDT	0
contains	contains	VBZ	0
all	all	DT	0
five	five	CD	0
pharmacophoric	pharmacophoric	CD	B-NP
region	region	NN	I-NP
was	was	VBD	0
synthesized	synthesized	VBN	0
by	by	IN	0
orjale	orjale	NN	B-NP
et	et	FW	0
al	al	FW	0
[	[	-LRB-	0
22	22	CD	0
]	]	-RRB-	0
.	.	.	0
This	This	DT	0
compound	compound	NN	B-NP
(	(	-LRB-	I-NP
1-	1-	NNP	I-NP
(	(	-LRB-	I-NP
phenylmethyl	phenylmethyl	LS	I-NP
)	)	-RRB-	I-NP
-2-piperizinyl	-2-piperizinyl	CD	I-NP
benzimidazola	benzimidazola	NN	I-NP
or	or	CC	0
lerisetron	lerisetron	CD	B-NP
)	)	-RRB-	0
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
figure	figure	NN	0
1and	1and	NN	0
is	is	VBZ	0
a	a	DT	0
potent	potent	JJ	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	B-NP
antagonist	antagonist	NN	I-NP
.	.	.	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
on	on	IN	0
this	this	DT	0
compound	compound	JJ	0
capable	capable	JJ	0
of	of	IN	0
forming	forming	VBG	B-NP
interaction	interaction	NN	I-NP
with	with	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
are	are	VBP	0
the	the	DT	0
distal	distal	JJ	B-NP
amino	amino	JJ	I-NP
group	group	NN	I-NP
,	,	,	0
a	a	DT	0
benzimidazole	benzimidazole	NN	B-NP
and	and	CC	0
a	a	DT	0
benzyl	benzyl	JJ	B-NP
group	group	NN	I-NP
in	in	IN	0
the	the	DT	0
benzimidazole	benzimidazole	NN	B-NP
n1	n1	NN	I-NP
position	position	NN	I-NP
.	.	.	0
While	While	IN	0
Lerisetron	Lerisetron	NNP	B-NP
contains	contains	VBZ	0
no	no	DT	0
carbonyl	carbonyl	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
the	the	DT	0
second	second	JJ	0
nitrogen	nitrogen	NN	B-NP
contained	contained	VBN	0
in	in	IN	0
the	the	DT	0
benzimidazole	benzimidazole	JJ	B-NP
heterocycle	heterocycle	NN	I-NP
could	could	MD	0
act	act	VB	0
as	as	IN	0
bioisostere	bioisostere	NN	B-NP
of	of	IN	0
this	this	DT	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
[	[	-LRB-	0
22	22	CD	0
]	]	-RRB-	0
.	.	.	0
orjale	orjale	NN	B-NP
demonstrated	demonstrated	VBD	0
the	the	DT	0
importance	importance	NN	0
of	of	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
by	by	IN	0
synthesizing	synthesizing	JJ	0
several	several	JJ	0
N1	N1	NN	0
substituted	substituted	VBD	0
analogs	analogs	VBN	0
of	of	IN	0
Lerisetron	Lerisetron	NNP	B-NP
.	.	.	0
Removal	Removal	NN	0
of	of	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
produced	produced	VBD	0
a	a	DT	0
80-fold	80-fold	JJ	0
decrease	decrease	NN	0
in	in	IN	0
affinity	affinity	NN	B-NP
,	,	,	0
indicating	indicating	VBG	0
a	a	DT	0
role	role	NN	0
for	for	IN	0
this	this	DT	0
group	group	NN	0
in	in	IN	0
interacting	interacting	NN	0
with	with	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R.	R.	NNP	0
Other	Other	JJ	0
studies	studies	NNS	0
have	have	VBP	0
supported	supported	VBN	0
this	this	DT	0
observation	observation	NN	0
and	and	CC	0
suggest	suggest	VB	0
a	a	DT	0
more	more	RBR	0
specific	specific	JJ	0
electrostatic	electrostatic	JJ	B-NP
interaction	interaction	NN	I-NP
[	[	-LRB-	0
23	23	CD	0
]	]	-RRB-	0
.	.	.	0
While	While	IN	0
structure-activity	structure-activity	JJ	B-NP
relationship	relationship	NN	I-NP
study	study	NN	I-NP
and	and	CC	0
molecular	molecular	JJ	0
modeling	modeling	NNS	0
have	have	VBP	0
led	led	VBN	0
to	to	TO	0
the	the	DT	0
development	development	NN	0
of	of	IN	0
a	a	DT	0
detailed	detailed	JJ	0
pharmacophore	pharmacophore	JJ	B-NP
model	model	NN	I-NP
,	,	,	0
determining	determining	VBG	0
specific	specific	JJ	0
point	point	NN	B-NP
interaction	interaction	NN	I-NP
between	between	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
antagonists	antagonists	NNS	0
and	and	CC	0
binding	binding	JJ	0
site	site	NN	0
amino	amino	NN	0
acids	acids	NN	0
has	has	VBZ	0
proven	proven	VBN	0
difficult	difficult	JJ	0
.	.	.	0
mutagenesi	mutagenesi	NN	B-NP
study	study	NN	I-NP
have	have	VBP	0
identified	identified	VBN	0
the	the	DT	0
interaction	interaction	NN	0
of	of	IN	0
amino	amino	JJ	0
acids	acids	JJ	0
W89	W89	NN	B-NP
and	and	CC	0
R91	R91	CD	B-NP
in	in	IN	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
[	[	-LRB-	0
24	24	CD	0
23	23	CD	0
]	]	-RRB-	0
.	.	.	0
Studies	Studies	NNS	0
conducted	conducted	VBN	0
in	in	IN	0
our	our	PRP$	0
laboratory	laboratory	NN	0
have	have	VBP	0
identified	identified	VBN	0
three	three	CD	0
additional	additional	JJ	0
putative	putative	JJ	B-NP
binding	binding	JJ	I-NP
site	site	NN	I-NP
residue	residue	NN	I-NP
(	(	-LRB-	0
Y140	Y140	NNP	B-NP
,	,	,	0
Y142	Y142	NNP	B-NP
,	,	,	0
and	and	CC	0
Y152	Y152	CD	B-NP
)	)	-RRB-	0
[	[	-LRB-	0
25	25	CD	0
]	]	-RRB-	0
.	.	.	0
W89	W89	NNP	B-NP
and	and	CC	0
R91	R91	NNP	B-NP
are	are	VBP	0
present	present	JJ	0
in	in	IN	0
a	a	DT	0
conserved	conserved	JJ	0
region	region	NN	0
of	of	IN	0
ligand	ligand	NN	B-NP
gated	gated	VBN	I-NP
ion	ion	NN	I-NP
channel	channel	NN	I-NP
receptors	receptors	VBD	0
often	often	RB	0
referred	referred	VBN	0
to	to	TO	0
as	as	RB	0
loop	loop	JJ	0
D	D	NNP	0
[	[	-LRB-	0
24	24	CD	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
Similarly	Similarly	RB	0
,	,	,	0
Y140	Y140	NNP	B-NP
,	,	,	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
are	are	VBP	0
located	located	VBN	0
in	in	IN	0
the	the	DT	0
region	region	NN	B-NP
homologus	homologus	NN	I-NP
to	to	TO	0
nicotinic	nicotinic	JJ	B-NP
achr	achr	NN	I-NP
e	e	NN	I-NP
loop	loop	NN	I-NP
region	region	NN	I-NP
.	.	.	0
In	In	IN	0
this	this	DT	0
study	study	NN	0
,	,	,	0
we	we	PRP	0
have	have	VBP	0
endeavoured	endeavoured	VBN	0
to	to	TO	0
identify	identify	VB	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	JJ	0
interacting	interacting	NN	0
with	with	IN	0
the	the	DT	0
different	different	JJ	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
present	present	JJ	0
on	on	IN	0
the	the	DT	0
lerisetron	lerisetron	JJ	B-NP
molecule	molecule	NN	I-NP
in	in	IN	0
order	order	NN	0
to	to	TO	0
develop	develop	VB	0
a	a	DT	0
model	model	NN	0
for	for	IN	0
interaction	interaction	NN	0
of	of	IN	0
this	this	DT	0
compound	compound	NN	B-NP
with	with	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R.	R.	NNP	0
Using	Using	NNP	0
site	site	NN	0
directed	directed	VBD	0
mutagenesis	mutagenesis	VBN	0
in	in	IN	0
combination	combination	NN	0
with	with	IN	0
analogs	analogs	NN	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
we	we	PRP	0
have	have	VBP	0
identified	identified	VBN	0
amino	amino	JJ	0
acids	acids	NNS	0
that	that	WDT	0
appear	appear	VBP	0
to	to	TO	0
interact	interact	VB	0
selectively	selectively	RB	0
with	with	IN	0
the	the	DT	0
terminal	terminal	NN	0
amino	amino	NN	0
group	group	NN	0
,	,	,	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
and	and	CC	0
the	the	DT	0
aromatic	aromatic	JJ	B-NP
benzimidazole	benzimidazole	NN	I-NP
.	.	.	0
Results	Results	NNS	0
lerisetron	lerisetron	JJ	B-NP
whole	whole	JJ	I-NP
cell	cell	NN	I-NP
patch-clamp	patch-clamp	JJ	I-NP
experiment	experiment	NN	I-NP
functional	functional	JJ	I-NP
activity	activity	NN	I-NP
were	were	VBD	0
performed	performed	VBN	0
to	to	TO	0
test	test	VB	0
the	the	DT	0
lerisetron	lerisetron	NN	B-NP
functional	functional	JJ	I-NP
activity	activity	NN	I-NP
.	.	.	0
No	No	DT	0
response	response	NN	0
was	was	VBD	0
observed	observed	VBN	0
when	when	WRB	0
lerisetron	lerisetron	NN	B-NP
was	was	VBD	0
applied	applied	VBN	0
alone	alone	RB	0
(	(	-LRB-	0
data	data	NNS	0
not	not	RB	0
shown	shown	VBN	0
)	)	-RRB-	0
.	.	.	0
When	When	WRB	0
co-applied	co-applied	JJ	0
with	with	IN	0
5-HT	5-HT	NNP	0
,	,	,	0
lerisetron	lerisetron	NN	B-NP
inhibited	inhibited	VBD	0
the	the	DT	0
absolute	absolute	JJ	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
response	response	NN	0
with	with	IN	0
no	no	DT	0
apparent	apparent	JJ	0
alteration	alteration	NN	0
of	of	IN	0
the	the	DT	0
response	response	NN	B-NP
profile	profile	NN	I-NP
(	(	-LRB-	0
Figure	Figure	NNP	0
2	2	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
combination	combination	NN	0
of	of	IN	0
several	several	JJ	0
identical	identical	JJ	0
inhibition	inhibition	JJ	B-NP
experiment	experiment	NN	I-NP
produced	produced	VBD	0
a	a	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
of	of	IN	0
0.2	0.2	CD	0
±	±	CD	0
0.03	0.03	CD	0
lerisetron	lerisetron	JJ	B-NP
inhibition	inhibition	NN	I-NP
nm	nm	NN	I-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	JJ	0
induced	induced	JJ	0
response	response	NN	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
correspond	correspond	VBP	0
well	well	RB	0
with	with	IN	0
previously	previously	RB	0
reported	reported	VBN	0
data	data	NNS	0
for	for	IN	0
this	this	DT	0
compound	compound	NN	B-NP
[	[	-LRB-	0
22	22	CD	0
]	]	-RRB-	0
and	and	CC	0
verify	verify	VB	0
the	the	DT	0
lerisetron	lerisetron	NN	B-NP
competitive	competitive	JJ	I-NP
antagonist	antagonist	JJ	I-NP
action	action	NN	I-NP
.	.	.	0
Analogs	Analogs	NNP	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
have	have	VBP	0
been	been	VBN	0
shown	shown	VBN	0
to	to	TO	0
inhibit	inhibit	VB	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
in	in	IN	0
a	a	DT	0
similar	similar	JJ	0
manner	manner	NN	0
[	[	-LRB-	0
23	23	CD	0
]	]	-RRB-	0
.	.	.	0
Importance	Importance	NN	0
of	of	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	0
and	and	CC	0
distal	distal	JJ	0
piperazine	piperazine	JJ	0
nitrogen	nitrogen	NN	0
to	to	TO	0
binding	binding	VB	0
of	of	IN	0
lerisetron	lerisetron	VBG	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
lerisetron	lerisetron	JJ	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptors	receptors	NNS	0
was	was	VBD	0
determined	determined	VBN	0
to	to	TO	0
be	be	VB	0
0.8	0.8	CD	0
±	±	CD	0
0.19	0.19	CD	0
nM	nM	NNS	0
(	(	-LRB-	0
Figure	Figure	NNP	0
3and	3and	NNP	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
value	value	NN	0
agrees	agrees	VBZ	0
with	with	IN	0
previously	previously	RB	0
published	published	VBN	0
data	data	NNS	0
for	for	IN	0
this	this	DT	0
compound	compound	NN	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
for	for	IN	0
analogs	analogs	CD	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
under	under	IN	0
identical	identical	JJ	0
conditions	conditions	NNS	0
are	are	VBP	0
25	25	CD	0
±	±	CD	0
3.2	3.2	CD	0
nM	nM	JJ	0
and	and	CC	0
320	320	CD	0
±	±	CD	0
82	82	CD	0
nM	nM	JJ	0
respectively	respectively	NNS	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4A	4A	NNP	0
,	,	,	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
observed	observed	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
represents	represents	VBZ	0
the	the	DT	0
decreases	decreases	NN	0
in	in	IN	0
binding	binding	JJ	0
energy	energy	NN	0
resulting	resulting	VBG	0
from	from	IN	0
removal	removal	NN	0
of	of	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	0
group	group	NN	0
(	(	-LRB-	0
analog	analog	CD	0
1	1	CD	0
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
distal	distal	FW	0
piperazine	piperazine	FW	0
nitrogen	nitrogen	FW	0
(	(	-LRB-	0
analog	analog	CD	0
2	2	CD	0
)	)	-RRB-	0
.	.	.	0
Identification	Identification	NN	B-NP
of	of	IN	0
amino	amino	JJ	0
acids	acids	JJ	0
interacting	interacting	NN	0
with	with	IN	0
Lerisetron	Lerisetron	NNP	B-NP
In	In	IN	0
order	order	NN	0
to	to	TO	0
determine	determine	VB	0
the	the	DT	0
nature	nature	NN	0
of	of	IN	0
the	the	DT	0
amino	amino	JJ	0
acids	acids	JJ	0
interacting	interacting	NN	0
with	with	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
amino	amino	NN	I-NP
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
n-benzyl	n-benzyl	NN	I-NP
group	group	NN	I-NP
,	,	,	0
we	we	PRP	0
constructed	constructed	VBD	0
5-HT	5-HT	NNP	0
3AS	3AS	NNP	0
Rs	Rs	NNP	0
containing	containing	VBG	B-NP
mutation	mutation	NN	I-NP
at	at	IN	0
W89	W89	NNP	B-NP
,	,	,	0
R91	R91	NNP	B-NP
,	,	,	0
Y140	Y140	NNP	B-NP
,	,	,	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
.	.	.	0
Figure	Figure	NNP	0
3shows	3shows	NNP	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
by	by	IN	0
lerisetron	lerisetron	NN	B-NP
on	on	IN	0
wildtype	wildtype	NN	B-NP
and	and	CC	0
mutant	mutant	JJ	B-NP
receptor	receptor	NN	I-NP
.	.	.	0
For	For	IN	0
most	most	RBS	0
amino	amino	JJ	0
acids	acids	NNS	0
,	,	,	0
an	an	DT	0
alanine	alanine	JJ	B-NP
substitution	substitution	NN	I-NP
was	was	VBD	0
constructed	constructed	VBN	0
in	in	IN	0
order	order	NN	0
to	to	TO	0
effectively	effectively	RB	0
remove	remove	VB	0
any	any	DT	0
amino	amino	JJ	0
acid	acid	NN	B-NP
interaction	interaction	NN	I-NP
with	with	IN	0
the	the	DT	0
ligand	ligand	NN	B-NP
.	.	.	0
For	For	IN	0
W89	W89	NNP	B-NP
,	,	,	0
an	an	DT	0
alanine	alanine	JJ	B-NP
substitution	substitution	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
shown	shown	VBN	0
to	to	TO	0
prevent	prevent	VB	0
binding	binding	VBN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
;	;	:	0
therefore	therefore	RB	0
a	a	DT	0
less	less	RBR	0
severe	severe	JJ	0
mutation	mutation	NN	0
was	was	VBD	0
constructed	constructed	VBN	0
.	.	.	0
The	The	DT	0
W89F	W89F	JJ	0
mutation	mutation	NN	0
produces	produces	VBZ	0
a	a	DT	0
18-fold	18-fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
d	d	NN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NNS	0
(	(	-LRB-	0
18	18	CD	0
±	±	CD	0
2	2	CD	0
nM	nM	NN	0
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
W89Y	W89Y	JJ	0
mutation	mutation	NN	0
produces	produces	VBZ	0
a	a	DT	0
5.8-fold	5.8-fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
d	d	NNS	0
(	(	-LRB-	0
5.7	5.7	CD	0
±	±	CD	0
0.7	0.7	CD	0
nM	nM	NN	0
)	)	-RRB-	0
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
amino	amino	JJ	0
acid	acid	NN	0
R91	R91	NN	0
to	to	TO	0
alanine	alanine	VB	0
produced	produced	VBN	0
a	a	DT	0
5-fold	5-fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
d	d	NN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	FW	0
binding	binding	FW	0
(	(	-LRB-	0
4.9	4.9	CD	0
±	±	CD	0
0.7	0.7	CD	0
nM	nM	NN	0
)	)	-RRB-	0
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
agree	agree	VBP	0
well	well	RB	0
with	with	IN	0
previously	previously	RB	0
reported	reported	VBN	0
values	values	NNS	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
Alanine	Alanine	JJ	0
mutations	mutations	NNS	0
at	at	IN	0
the	the	DT	0
tyrosine	tyrosine	JJ	0
positions	positions	NNS	0
Y140	Y140	RB	0
,	,	,	0
Y142	Y142	NNP	0
and	and	CC	0
Y152	Y152	NNP	0
also	also	RB	0
produced	produced	VBN	0
minor	minor	JJ	0
increases	increases	NNS	0
in	in	IN	0
K	K	NNP	0
d	d	NN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	FW	0
binding	binding	FW	0
(	(	-LRB-	0
2.7	2.7	CD	0
±	±	CD	0
0.19	0.19	CD	0
nM	nM	NN	0
,	,	,	0
4.5	4.5	CD	0
±	±	CD	0
0.5	0.5	CD	0
nM	nM	JJ	0
and	and	CC	0
7.8	7.8	CD	0
±	±	CD	0
1.1	1.1	CD	0
nM	nM	JJ	0
respectively	respectively	NN	0
)	)	-RRB-	0
[	[	-LRB-	0
25	25	CD	0
]	]	-RRB-	0
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Only	Only	RB	0
small	small	JJ	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
were	were	VBD	0
observed	observed	VBN	0
for	for	IN	0
the	the	DT	0
Y140A	Y140A	JJ	0
mutation	mutation	NN	0
while	while	IN	0
the	the	DT	0
Y142A	Y142A	NNP	0
and	and	CC	0
Y152A	Y152A	CD	0
mutations	mutations	NNS	0
produced	produced	VBD	0
large	large	JJ	0
increases	increases	NNS	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
(	(	-LRB-	0
Table	Table	NNP	0
1and	1and	NNP	0
Figure	Figure	NNP	0
3	3	CD	0
)	)	-RRB-	0
.	.	.	0
For	For	IN	0
W89F	W89F	NNP	0
and	and	CC	0
W89Y	W89Y	NNP	0
,	,	,	0
the	the	DT	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	VBD	0
observed	observed	VBN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
were	were	VBD	0
much	much	RB	0
smaller	smaller	JJR	0
than	than	IN	0
for	for	IN	0
the	the	DT	0
alanine	alanine	JJ	0
mutations	mutations	NNS	0
at	at	IN	0
Y142A	Y142A	NNP	0
and	and	CC	0
Y152A	Y152A	NNP	0
,	,	,	0
as	as	RB	0
would	would	MD	0
be	be	VB	0
expected	expected	VBN	0
for	for	IN	0
the	the	DT	0
less	less	RBR	0
severe	severe	JJ	0
nature	nature	NN	0
of	of	IN	0
these	these	DT	0
mutations	mutations	NN	0
.	.	.	0
The	The	DT	0
changes	changes	NNS	0
were	were	VBD	0
,	,	,	0
however	however	RB	0
significant	significant	JJ	0
(	(	-LRB-	0
p	p	JJ	0
<	<	SYM	0
0.001	0.001	NN	0
in	in	IN	0
both	both	DT	0
cases	cases	NNS	0
)	)	-RRB-	0
and	and	CC	0
are	are	VBP	0
similar	similar	JJ	0
to	to	TO	0
the	the	DT	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
d	d	VBD	0
reported	reported	VBN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	0
.	.	.	0
The	The	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
on	on	IN	0
the	the	DT	0
W89F	W89F	JJ	0
mutant	mutant	JJ	0
receptor	receptor	NN	0
was	was	VBD	0
4.8	4.8	CD	0
±	±	CD	0
0.56	0.56	CD	0
fold	fold	NNS	0
and	and	CC	0
the	the	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
on	on	IN	0
the	the	DT	0
W89Y	W89Y	JJ	0
receptor	receptor	NN	0
was	was	VBD	0
3.6	3.6	CD	0
±	±	CD	0
0.4	0.4	CD	0
fold	fold	NNS	0
.	.	.	0
The	The	DT	0
R91A	R91A	CD	0
mutant	mutant	NNS	0
produced	produced	VBD	0
an	an	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
of	of	IN	0
7.6	7.6	CD	0
±	±	CD	0
1.5	1.5	CD	0
fold	fold	NNS	0
as	as	RB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
wildtype	wildtype	JJ	0
receptor	receptor	NN	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
indicated	indicated	VBD	0
potential	potential	JJ	0
interactions	interactions	NNS	0
of	of	IN	0
lerisetron	lerisetron	NN	0
with	with	IN	0
W89	W89	NNP	0
,	,	,	0
R91	R91	NNP	0
,	,	,	0
Y142	Y142	NNP	0
and	and	CC	0
Y152	Y152	NNP	0
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
W89	W89	CD	0
As	As	IN	0
mentioned	mentioned	VBN	0
above	above	IN	0
,	,	,	0
the	the	DT	0
lack	lack	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
to	to	TO	0
W89A	W89A	CD	0
mutant	mutant	CD	0
receptors	receptors	NNS	0
necessitated	necessitated	VBD	0
the	the	DT	0
use	use	NN	0
of	of	IN	0
W89F	W89F	NNP	0
and	and	CC	0
W89Y	W89Y	CD	0
mutations	mutations	NNS	0
to	to	TO	0
analyze	analyze	VB	0
functional	functional	JJ	0
group	group	NN	0
interactions	interactions	NNS	0
.	.	.	0
The	The	DT	0
effects	effects	NNS	0
of	of	IN	0
these	these	DT	0
mutations	mutations	NN	0
on	on	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analogs	analogs	CD	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
are	are	VBP	0
shown	shown	VBN	0
in	in	IN	0
figure	figure	NN	0
4B	4B	NN	0
,	,	,	0
4Cand	4Cand	NNP	0
Table	Table	NNP	0
1	1	CD	0
.	.	.	0
Analog	Analog	NNP	0
1	1	CD	0
inhibited	inhibited	NNS	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
to	to	TO	0
W89F	W89F	CD	0
receptors	receptors	NNS	0
with	with	IN	0
a	a	DT	0
K	K	NNP	0
i	i	NN	0
of	of	IN	0
170	170	CD	0
±	±	CD	0
54	54	CD	0
nM	nM	NNS	0
(	(	-LRB-	0
7	7	CD	0
±	±	CD	0
3.2	3.2	CD	0
fold	fold	JJ	0
increase	increase	NN	0
,	,	,	0
p	p	CD	0
<	<	SYM	0
0.001	0.001	CD	0
)	)	-RRB-	0
and	and	CC	0
W89Y	W89Y	CD	0
receptors	receptors	NNS	0
with	with	IN	0
a	a	DT	0
K	K	NNP	0
i	i	NN	0
of	of	IN	0
81	81	CD	0
±	±	CD	0
14	14	CD	0
nM	nM	NNS	0
(	(	-LRB-	0
3.2	3.2	CD	0
±	±	CD	0
0.6	0.6	CD	0
fold	fold	JJ	0
increase	increase	NN	0
,	,	,	0
p	p	CD	0
<	<	SYM	0
0.001	0.001	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
reflects	reflects	VBZ	0
a	a	DT	0
significant	significant	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
and	and	CC	0
reflects	reflects	VBZ	0
a	a	DT	0
potential	potential	JJ	0
interaction	interaction	NN	0
of	of	IN	0
analog	analog	CD	0
1	1	CD	0
with	with	IN	0
W89	W89	CD	0
.	.	.	0
The	The	DT	0
strength	strength	NN	0
of	of	IN	0
this	this	DT	0
interaction	interaction	NN	0
is	is	VBZ	0
apparently	apparently	RB	0
similar	similar	JJ	0
to	to	TO	0
the	the	DT	0
strength	strength	NN	0
of	of	IN	0
the	the	DT	0
interaction	interaction	NN	0
with	with	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
and	and	CC	0
lerisetron	lerisetron	NN	0
since	since	IN	0
the	the	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	0
is	is	VBZ	0
similar	similar	JJ	0
in	in	IN	0
both	both	DT	0
cases	cases	NNS	0
.	.	.	0
Analog	Analog	NNP	0
2	2	CD	0
also	also	RB	0
showed	showed	VBD	0
a	a	DT	0
significant	significant	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
W89F	W89F	NNP	0
and	and	CC	0
W89Y	W89Y	CD	0
mutations	mutations	NNS	0
.	.	.	0
The	The	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	0
for	for	IN	0
W89F	W89F	NNP	0
(	(	-LRB-	0
5.1	5.1	CD	0
±	±	CD	0
1.3	1.3	CD	0
fold	fold	NN	0
,	,	,	0
p	p	CD	0
<	<	SYM	0
0.05	0.05	CD	0
)	)	-RRB-	0
was	was	VBD	0
similar	similar	JJ	0
to	to	TO	0
that	that	WDT	0
observed	observed	VBD	0
for	for	IN	0
lerisetron	lerisetron	NN	0
and	and	CC	0
analog	analog	CD	0
1	1	CD	0
.	.	.	0
The	The	DT	0
W89Y	W89Y	JJ	0
mutation	mutation	NN	0
produced	produced	VBD	0
a	a	DT	0
6.8	6.8	CD	0
±	±	CD	0
1.6	1.6	CD	0
fold	fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
(	(	-LRB-	0
p	p	CD	0
<	<	SYM	0
0.05	0.05	CD	0
)	)	-RRB-	0
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NNS	0
appear	appear	VBP	0
to	to	TO	0
form	form	VB	0
similar	similar	JJ	0
interactions	interactions	NNS	0
with	with	IN	0
W89	W89	CD	0
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
R91	R91	NNP	0
Mutation	Mutation	NNP	0
of	of	IN	0
R91	R91	CD	0
to	to	TO	B-NP
alanine	alanine	VB	I-NP
(	(	-LRB-	0
to	to	IN	B-NP
alanine	alanine	NN	I-NP
)	)	-RRB-	0
resulted	resulted	VBD	0
in	in	IN	0
a	a	DT	0
significant	significant	JJ	0
,	,	,	0
but	but	CC	0
small	small	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
of	of	IN	0
7.6	7.6	CD	0
±	±	CD	0
1.5	1.5	CD	0
fold	fold	NNS	0
(	(	-LRB-	0
p	p	CD	0
<	<	SYM	0
0.01	0.01	CD	0
)	)	-RRB-	0
.	.	.	0
Figure	Figure	NN	0
4Dshows	4Dshows	VBZ	0
the	the	DT	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
by	by	IN	0
analogs	analogs	CD	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
at	at	IN	0
R91A	R91A	CD	0
mutant	mutant	CD	0
receptors	receptors	NNS	0
.	.	.	0
No	No	DT	0
significant	significant	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
observed	observed	VBN	0
on	on	IN	0
these	these	DT	0
receptors	receptors	NN	0
for	for	IN	0
either	either	DT	0
analog	analog	JJ	0
1	1	CD	0
(	(	-LRB-	0
0.9	0.9	CD	0
±	±	CD	0
0.28	0.28	CD	0
fold	fold	CD	0
)	)	-RRB-	0
or	or	CC	0
analog	analog	CD	0
2	2	CD	0
(	(	-LRB-	0
0.56	0.56	CD	0
±	±	CD	0
0.14	0.14	CD	0
fold	fold	CD	0
)	)	-RRB-	0
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
as	as	RB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
wildtype	wildtype	JJ	0
receptor	receptor	NN	0
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
Y142	Y142	NNP	0
Mutation	Mutation	NNP	0
of	of	IN	0
Y142	Y142	CD	0
to	to	TO	0
alanine	alanine	VB	0
produced	produced	VBN	0
one	one	CD	0
of	of	IN	0
the	the	DT	0
largest	largest	JJS	0
observed	observed	JJ	0
changes	changes	NNS	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	NNS	0
(	(	-LRB-	0
Figure	Figure	NNP	0
3and	3and	NNP	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	VBD	0
obtained	obtained	VBN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
was	was	VBD	0
130	130	CD	0
±	±	CD	0
28	28	CD	0
nM	nM	NN	0
,	,	,	0
reflecting	reflecting	VBG	0
a	a	DT	0
change	change	NN	0
of	of	IN	0
160	160	CD	0
±	±	CD	0
37	37	CD	0
fold	fold	NNS	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
receptors	receptors	NNS	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
analog	analog	CD	0
1	1	CD	0
,	,	,	0
in	in	IN	0
contrast	contrast	NN	0
,	,	,	0
increased	increased	VBD	0
only	only	RB	0
6.8	6.8	CD	0
±	±	CD	0
2.3	2.3	CD	0
fold	fold	NNS	0
(	(	-LRB-	0
p	p	CD	0
<	<	SYM	0
0.01	0.01	CD	0
)	)	-RRB-	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
this	this	DT	0
mutation	mutation	NN	0
(	(	-LRB-	0
Figure	Figure	NNP	0
4Eand	4Eand	NNP	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
showed	showed	VBD	0
a	a	DT	0
similar	similar	JJ	0
change	change	NN	0
of	of	IN	0
17	17	CD	0
±	±	CD	0
0.77	0.77	CD	0
fold	fold	NNS	0
(	(	-LRB-	0
p	p	CD	0
<	<	SYM	0
0.01	0.01	CD	0
)	)	-RRB-	0
.	.	.	0
While	While	IN	0
these	these	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
are	are	VBP	0
significantly	significantly	RB	0
different	different	JJ	0
from	from	IN	0
wildtype	wildtype	JJ	0
values	values	NNS	0
for	for	IN	0
each	each	DT	0
analog	analog	NN	0
,	,	,	0
the	the	DT	0
lack	lack	NN	0
of	of	IN	0
larger	larger	JJR	0
effects	effects	NNS	0
suggests	suggests	VBZ	0
that	that	IN	0
neither	neither	DT	0
analog	analog	JJ	0
1	1	CD	0
nor	nor	CC	0
analog	analog	CD	0
2	2	CD	0
bind	bind	NN	0
as	as	IN	0
strongly	strongly	RB	0
as	as	IN	0
lerisetron	lerisetron	VBG	0
to	to	TO	0
Y142	Y142	CD	0
.	.	.	0
Mutation	Mutation	NN	0
of	of	IN	0
Y152	Y152	CD	0
The	The	DT	0
Y152A	Y152A	JJ	0
mutation	mutation	NN	0
showed	showed	VBD	0
the	the	DT	0
most	most	RBS	0
variability	variability	JJ	0
in	in	IN	0
its	its	PRP$	0
effects	effects	NNS	0
on	on	IN	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
for	for	IN	0
lerisetron	lerisetron	NN	0
,	,	,	0
analog	analog	CD	0
1	1	CD	0
and	and	CC	0
analog	analog	CD	0
2	2	CD	0
(	(	-LRB-	0
Figure	Figure	NNP	0
3	3	CD	0
,	,	,	0
Figure	Figure	NNP	0
4Fand	4Fand	NNP	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Lerisetron	Lerisetron	JJ	0
inhibited	inhibited	NNS	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	JJ	0
binding	binding	NN	0
with	with	IN	0
a	a	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
of	of	IN	0
150	150	CD	0
±	±	CD	0
36	36	CD	0
;	;	:	0
an	an	DT	0
increase	increase	NN	0
of	of	IN	0
190	190	CD	0
±	±	CD	0
43	43	CD	0
fold	fold	NNS	0
compared	compared	VBN	0
to	to	TO	0
wildtype	wildtype	VB	0
values	values	NNS	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
analog	analog	CD	0
1	1	CD	0
increased	increased	VBN	0
from	from	IN	0
25	25	CD	0
±	±	CD	0
3.2	3.2	CD	0
nM	nM	NNS	0
(	(	-LRB-	0
wildtype	wildtype	LS	0
)	)	-RRB-	0
to	to	TO	0
2.5	2.5	CD	0
±	±	CD	0
0.40	0.40	CD	0
μM	μM	NN	0
.	.	.	0
This	This	DT	0
change	change	NN	0
of	of	IN	0
100	100	CD	0
±	±	CD	0
16	16	CD	0
fold	fold	NN	0
is	is	VBZ	0
slightly	slightly	RB	0
smaller	smaller	JJR	0
,	,	,	0
but	but	CC	0
not	not	RB	0
significantly	significantly	RB	0
different	different	JJ	0
from	from	IN	0
the	the	DT	0
relative	relative	JJ	0
change	change	NN	0
observed	observed	VBD	0
for	for	IN	0
lerisetron	lerisetron	NN	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
increased	increased	VBN	0
from	from	IN	0
0.32	0.32	CD	0
±	±	CD	0
0.08	0.08	CD	0
μM	μM	NN	0
on	on	IN	0
wildtype	wildtype	VBG	0
to	to	TO	0
13	13	CD	0
±	±	CD	0
4.2	4.2	CD	0
μM	μM	NN	0
on	on	IN	0
Y152A	Y152A	FW	0
mutant	mutant	FW	0
receptors	receptors	FW	0
(	(	-LRB-	0
40	40	CD	0
±	±	CD	0
12	12	CD	0
fold	fold	JJ	0
increase	increase	NN	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
increase	increase	NN	0
observed	observed	VBD	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
was	was	VBD	0
significantly	significantly	RB	0
less	less	JJR	0
than	than	IN	0
that	that	WDT	0
observed	observed	VBD	0
for	for	IN	0
both	both	DT	0
lerisetron	lerisetron	NN	0
and	and	CC	0
analog	analog	CD	0
1	1	CD	0
.	.	.	0
The	The	DT	0
smaller	smaller	JJR	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
suggests	suggests	VBZ	0
that	that	IN	0
analog	analog	CD	0
2	2	CD	0
binds	binds	JJ	0
weakly	weakly	NN	0
to	to	TO	0
Y152	Y152	CD	0
while	while	IN	0
lerisetron	lerisetron	NN	0
and	and	CC	0
analog	analog	CD	0
1	1	CD	0
bind	bind	NN	0
more	more	RBR	0
tightly	tightly	RB	0
.	.	.	0
Discussion	Discussion	NNP	0
Functional	Functional	NNP	0
group	group	NN	0
interactions	interactions	NNS	0
of	of	IN	0
W89	W89	CD	0
The	The	DT	0
W89F	W89F	JJ	0
mutation	mutation	NN	0
produced	produced	VBD	0
a	a	DT	0
significant	significant	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NNS	0
.	.	.	0
The	The	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	0
was	was	VBD	0
similar	similar	JJ	0
in	in	IN	0
all	all	DT	0
cases	cases	NNS	0
.	.	.	0
In	In	IN	0
addition	addition	NN	0
,	,	,	0
the	the	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
identical	identical	JJ	0
to	to	TO	0
the	the	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
d	d	NN	0
that	that	WDT	0
has	has	VBZ	0
been	been	VBN	0
observed	observed	VBN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
binding	binding	NN	0
on	on	IN	0
this	this	DT	0
mutant	mutant	NN	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
Alterations	Alterations	NNP	0
in	in	IN	0
K	K	NNP	0
i	i	VBZ	0
resulting	resulting	VBG	0
from	from	IN	0
the	the	DT	0
W89Y	W89Y	JJ	0
mutation	mutation	NN	0
were	were	VBD	0
slightly	slightly	RB	0
less	less	RBR	0
,	,	,	0
however	however	RB	0
the	the	DT	0
change	change	NN	0
was	was	VBD	0
again	again	RB	0
the	the	DT	0
same	same	JJ	0
for	for	IN	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
analog	analog	CD	0
1	1	CD	0
and	and	CC	0
analog	analog	CD	0
2	2	CD	0
.	.	.	0
These	These	DT	0
data	data	NNS	0
suggest	suggest	VBP	0
that	that	IN	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NNS	0
form	form	VBP	0
binding	binding	JJ	0
site	site	NN	0
interactions	interactions	NNS	0
with	with	IN	0
W89	W89	CD	B-NP
.	.	.	0
The	The	DT	0
interaction	interaction	NN	0
between	between	IN	0
lerisetron	lerisetron	NN	B-NP
and	and	CC	0
W89	W89	NNP	B-NP
is	is	VBZ	0
unlikely	unlikely	JJ	0
to	to	TO	0
be	be	VB	0
via	via	IN	0
the	the	DT	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
n-benzyl	n-benzyl	NN	I-NP
since	since	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
1	1	CD	0
was	was	VBD	0
also	also	RB	0
altered	altered	VBN	0
by	by	IN	0
this	this	DT	0
mutation	mutation	NN	0
.	.	.	0
The	The	DT	0
same	same	JJ	0
argument	argument	NN	0
can	can	MD	0
be	be	VB	0
made	made	VBN	0
for	for	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
piperazine	piperazine	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
since	since	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
also	also	RB	0
increased	increased	VBN	0
.	.	.	0
The	The	DT	0
portion	portion	NN	0
of	of	IN	0
the	the	DT	0
molecule	molecule	JJ	B-NP
common	common	JJ	0
to	to	TO	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NN	0
,	,	,	0
the	the	DT	0
aromatic	aromatic	JJ	B-NP
benzimidazole	benzimidazole	NN	I-NP
,	,	,	0
is	is	VBZ	0
thus	thus	RB	0
the	the	DT	0
most	most	RBS	0
likely	likely	JJ	0
point	point	NN	0
of	of	IN	0
interaction	interaction	NN	0
for	for	IN	0
W89	W89	CD	B-NP
.	.	.	0
Functional	Functional	JJ	0
group	group	NN	0
interactions	interactions	NNS	0
of	of	IN	0
R91	R91	CD	0
The	The	DT	0
R91A	R91A	JJ	0
mutation	mutation	NN	0
increased	increased	VBD	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
for	for	IN	0
lerisetron	lerisetron	JJ	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
binding	binding	NN	0
by	by	IN	0
7.6	7.6	CD	0
fold	fold	NNS	0
.	.	.	0
This	This	DT	0
is	is	VBZ	0
a	a	DT	0
moderately	moderately	RB	0
small	small	JJ	0
change	change	NN	0
for	for	IN	0
an	an	DT	0
alanine	alanine	JJ	0
mutation	mutation	NN	0
,	,	,	0
particularly	particularly	RB	0
considering	considering	VBG	0
that	that	IN	0
the	the	DT	0
smallest	smallest	JJS	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
removal	removal	NN	0
of	of	IN	0
a	a	DT	0
functional	functional	JJ	0
group	group	NN	0
on	on	IN	0
lerisetron	lerisetron	NNS	0
(	(	-LRB-	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	0
group	group	NN	0
)	)	-RRB-	0
was	was	VBD	0
31	31	CD	0
fold	fold	NNS	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
therefore	therefore	RB	0
likely	likely	JJ	0
that	that	IN	0
this	this	DT	0
interaction	interaction	NN	0
is	is	VBZ	0
either	either	RB	0
extremely	extremely	RB	0
weak	weak	JJ	0
or	or	CC	0
the	the	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
is	is	VBZ	0
the	the	DT	0
result	result	NN	0
of	of	IN	0
a	a	DT	0
structural	structural	JJ	0
change	change	NN	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
.	.	.	0
Previous	Previous	JJ	0
studies	studies	NNS	0
concluded	concluded	VBD	0
that	that	IN	0
R91	R91	NNP	0
was	was	VBD	0
an	an	DT	0
important	important	JJ	0
interaction	interaction	NN	0
for	for	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
agonist	agonist	VBD	0
5-hydroxytryptamine	5-hydroxytryptamine	CD	B-NP
(	(	-LRB-	0
5-hydroxytryptamine	5-hydroxytryptamine	NN	B-NP
)	)	-RRB-	0
,	,	,	0
since	since	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
5-HT	5-HT	NNP	0
inhibition	inhibition	VBD	0
increased	increased	VBN	0
over	over	IN	0
3000	3000	CD	0
fold	fold	NN	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
R91A	R91A	JJ	0
mutation	mutation	NN	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
A	A	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
d	d	NN	0
for	for	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBP	0
binding	binding	VBG	0
to	to	TO	0
R91A	R91A	NNP	0
was	was	VBD	0
also	also	RB	0
observed	observed	VBD	0
.	.	.	0
In	In	IN	0
order	order	NN	0
to	to	TO	0
determine	determine	VB	0
whether	whether	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	0
or	or	CC	0
distal	distal	JJ	0
piperazine	piperazine	JJ	0
nitrogen	nitrogen	NN	0
of	of	IN	0
lerisetron	lerisetron	NN	0
was	was	VBD	0
involved	involved	VBN	0
in	in	IN	0
an	an	DT	0
interaction	interaction	NN	0
with	with	IN	0
R91	R91	NNP	0
,	,	,	0
we	we	PRP	0
tested	tested	VBD	0
both	both	DT	0
analog	analog	JJ	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
on	on	IN	0
R91A	R91A	CD	0
mutant	mutant	CD	0
receptors	receptors	NNS	0
.	.	.	0
No	No	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
either	either	DT	0
compound	compound	NN	0
.	.	.	0
This	This	DT	0
result	result	NN	0
makes	makes	VBZ	0
it	it	PRP	0
much	much	RB	0
more	more	RBR	0
difficult	difficult	JJ	0
to	to	TO	0
assign	assign	VB	0
the	the	DT	0
correct	correct	JJ	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
to	to	TO	0
this	this	DT	0
amino	amino	JJ	0
acid	acid	NN	B-NP
since	since	IN	0
it	it	PRP	0
suggests	suggests	VBZ	0
that	that	IN	0
one	one	CD	0
or	or	CC	0
both	both	DT	0
of	of	IN	0
the	the	DT	0
compounds	compounds	NN	0
is	is	VBZ	0
no	no	RB	0
longer	longer	RB	0
binding	binding	VBG	0
the	the	DT	0
receptor	receptor	NN	B-NP
in	in	IN	0
precisely	precisely	RB	0
the	the	DT	0
same	same	JJ	0
manner	manner	NN	0
as	as	IN	0
lerisetron	lerisetron	NN	B-NP
.	.	.	0
Considering	Considering	VBG	0
the	the	DT	0
small	small	JJ	0
change	change	NN	0
observed	observed	VBD	0
for	for	IN	0
lerisetron	lerisetron	JJ	B-NP
binding	binding	NN	I-NP
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
this	this	DT	0
mutation	mutation	NN	0
,	,	,	0
even	even	RB	0
a	a	DT	0
slight	slight	JJ	0
molecule	molecule	NN	B-NP
reorientation	reorientation	NN	I-NP
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
could	could	MD	0
result	result	VB	0
in	in	IN	0
the	the	DT	0
loss	loss	NN	0
of	of	IN	0
this	this	DT	0
interaction	interaction	NN	0
.	.	.	0
Functional	Functional	JJ	0
group	group	NN	0
interactions	interactions	NNS	0
of	of	IN	0
Y142	Y142	CD	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
for	for	IN	0
inhibition	inhibition	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	JJ	0
binding	binding	NN	0
by	by	IN	0
analogs	analogs	CD	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
were	were	VBD	0
altered	altered	VBN	0
only	only	RB	0
slightly	slightly	RB	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
.	.	.	0
The	The	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
,	,	,	0
however	however	RB	0
,	,	,	0
was	was	VBD	0
considerably	considerably	RB	0
larger	larger	JJR	0
(	(	-LRB-	0
160	160	CD	0
fold	fold	CD	0
)	)	-RRB-	0
and	and	CC	0
is	is	VBZ	0
indicative	indicative	VBN	0
of	of	IN	0
an	an	DT	0
important	important	JJ	0
interaction	interaction	NN	0
of	of	IN	0
the	the	DT	0
compound	compound	NN	0
with	with	IN	0
Y142	Y142	CD	0
.	.	.	0
The	The	DT	0
lack	lack	NN	0
of	of	IN	0
a	a	DT	0
large	large	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
both	both	DT	0
analogs	analogs	NN	0
makes	makes	VBZ	0
it	it	PRP	0
difficult	difficult	JJ	0
to	to	TO	0
interpret	interpret	VB	0
this	this	DT	0
data	data	NNS	0
since	since	IN	0
one	one	CD	0
or	or	CC	0
both	both	DT	0
of	of	IN	0
the	the	DT	0
compounds	compounds	NN	0
appears	appears	VBZ	0
to	to	TO	0
be	be	VB	0
interacting	interacting	VBN	0
differently	differently	RB	0
with	with	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
than	than	IN	0
lerisetron	lerisetron	NN	0
.	.	.	0
Analogs	Analogs	NNP	0
1	1	CD	0
and	and	CC	0
2	2	CD	0
differ	differ	NN	0
from	from	IN	0
each	each	DT	0
other	other	JJ	0
both	both	CC	0
in	in	IN	0
the	the	DT	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
contained	contained	VBN	0
in	in	IN	0
the	the	DT	0
molecule	molecule	NN	B-NP
and	and	CC	0
their	their	PRP$	0
structural	structural	JJ	B-NP
similarity	similarity	NN	I-NP
to	to	TO	0
lerisetron	lerisetron	VB	0
.	.	.	0
Analog	Analog	NNP	0
2	2	CD	0
is	is	VBZ	0
most	most	RBS	0
similar	similar	JJ	0
in	in	IN	0
overall	overall	JJ	0
structure	structure	NN	0
.	.	.	0
The	The	DT	0
distal	distal	JJ	B-NP
amino	amino	NNS	I-NP
nitrogen	nitrogen	VBP	I-NP
oxygen	oxygen	NN	I-NP
substitution	substitution	NN	I-NP
alters	alters	VBG	0
the	the	DT	0
potential	potential	JJ	B-NP
interaction	interaction	NN	I-NP
formed	formed	VBN	0
at	at	IN	0
this	this	DT	0
position	position	NN	0
,	,	,	0
but	but	CC	0
is	is	VBZ	0
likely	likely	JJ	0
to	to	TO	0
have	have	VB	0
a	a	DT	0
small	small	JJ	0
effect	effect	NN	0
on	on	IN	0
the	the	DT	0
overall	overall	JJ	0
size	size	NN	0
and	and	CC	0
shape	shape	NN	0
of	of	IN	0
the	the	DT	0
molecule	molecule	NN	B-NP
.	.	.	0
Analog	Analog	NNP	0
1	1	CD	0
is	is	VBZ	0
far	far	RB	0
less	less	RBR	0
similar	similar	JJ	0
to	to	TO	0
lerisetron	lerisetron	VB	0
and	and	CC	0
more	more	RBR	0
similar	similar	JJ	0
to	to	TO	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	B-NP
antagonist	antagonist	NN	I-NP
granisetron	granisetron	NN	I-NP
.	.	.	0
previous	previous	JJ	B-NP
study	study	NN	I-NP
have	have	VBP	0
shown	shown	VBN	0
that	that	IN	0
the	the	DT	0
binding	binding	NN	0
of	of	IN	0
granisetron	granisetron	NN	B-NP
is	is	VBZ	0
not	not	RB	0
affected	affected	VBN	0
by	by	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
[	[	-LRB-	0
25	25	CD	0
]	]	-RRB-	0
.	.	.	0
Analog	Analog	NNP	0
1	1	CD	0
may	may	MD	0
bind	bind	VB	0
more	more	RBR	0
similar	similar	JJ	0
to	to	TO	0
granisetron	granisetron	VB	0
than	than	IN	0
lerisetron	lerisetron	NN	B-NP
and	and	CC	0
thus	thus	RB	0
would	would	MD	0
be	be	VB	0
unaffected	unaffected	VBN	0
by	by	IN	0
mutations	mutations	NNS	0
at	at	IN	0
Y142	Y142	CD	B-NP
.	.	.	0
This	This	DT	0
is	is	VBZ	0
less	less	RBR	0
likely	likely	JJ	0
to	to	TO	0
be	be	VB	0
the	the	DT	0
case	case	NN	0
with	with	IN	0
analog	analog	CD	0
2	2	CD	0
.	.	.	0
The	The	DT	0
strength	strength	NN	0
of	of	IN	0
the	the	DT	0
putative	putative	JJ	B-NP
interaction	interaction	NN	I-NP
at	at	IN	0
Y142	Y142	NNP	B-NP
can	can	MD	0
be	be	VB	0
identified	identified	VBN	0
by	by	IN	0
examining	examining	VBG	0
the	the	DT	0
change	change	NN	0
in	in	IN	0
binding	binding	VBG	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
.	.	.	0
The	The	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
produced	produced	VBD	0
a	a	DT	0
160	160	CD	0
fold	fold	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	FW	0
.	.	.	0
This	This	DT	0
change	change	NN	0
reflects	reflects	VBZ	0
the	the	DT	0
binding	binding	JJ	0
energy	energy	NN	B-NP
lost	lost	VBD	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
alanine	alanine	JJ	B-NP
substitution	substitution	NN	I-NP
.	.	.	0
The	The	DT	0
observed	observed	JJ	0
change	change	NN	0
in	in	IN	0
Ki	Ki	NNP	B-NP
on	on	IN	0
wt	wt	JJ	B-NP
receptor	receptor	NN	I-NP
is	is	VBZ	0
much	much	RB	0
larger	larger	JJR	0
than	than	IN	0
that	that	WDT	0
observed	observed	VBD	0
for	for	IN	0
removal	removal	NN	0
of	of	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
(	(	-LRB-	0
31	31	CD	0
fold	fold	CD	0
)	)	-RRB-	0
,	,	,	0
but	but	CC	0
is	is	VBZ	0
similar	similar	JJ	0
to	to	TO	0
that	that	WDT	0
observed	observed	VBD	0
for	for	IN	0
distal	distal	JJ	B-NP
amino	amino	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
substitution	substitution	NN	I-NP
in	in	IN	0
analog	analog	CD	0
2	2	CD	0
(	(	-LRB-	0
400	400	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
Taken	Taken	VBN	0
together	together	RP	0
with	with	IN	0
the	the	DT	0
close	close	JJ	0
structural	structural	JJ	B-NP
similarity	similarity	NN	I-NP
of	of	IN	0
analog	analog	CD	0
2	2	CD	0
to	to	TO	0
lerisetron	lerisetron	VB	0
,	,	,	0
it	it	PRP	0
can	can	MD	0
be	be	VB	0
concluded	concluded	VBN	0
that	that	IN	0
comparison	comparison	NN	0
of	of	IN	0
analog	analog	CD	0
2	2	CD	0
and	and	CC	0
lerisetron	lerisetron	NN	B-NP
should	should	MD	0
provide	provide	VB	0
the	the	DT	0
best	best	JJS	0
means	means	NNS	0
of	of	IN	0
identifying	identifying	VBG	0
the	the	DT	0
interaction	interaction	NN	0
at	at	IN	0
Y142	Y142	CD	B-NP
.	.	.	0
No	No	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
was	was	VBD	0
observed	observed	VBN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
indicating	indicating	VBG	0
a	a	DT	0
lack	lack	NN	0
of	of	IN	0
any	any	DT	0
significant	significant	JJ	0
interaction	interaction	NN	0
of	of	IN	0
this	this	DT	0
compound	compound	NN	B-NP
with	with	IN	0
Y142	Y142	CD	B-NP
.	.	.	0
These	These	DT	0
data	data	NNS	0
support	support	VBP	0
our	our	PRP$	0
hypothesis	hypothesis	NN	0
that	that	IN	0
Y142	Y142	CD	B-NP
interacts	interacts	NN	0
with	with	IN	0
the	the	DT	0
lerisetron	lerisetron	NN	B-NP
distal	distal	JJ	I-NP
piperazine	piperazine	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
A	A	DT	0
second	second	JJ	0
amino	amino	JJ	0
acid	acid	NN	B-NP
may	may	MD	0
also	also	RB	0
be	be	VB	0
involved	involved	VBN	0
since	since	IN	0
the	the	DT	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	JJ	B-NP
binding	binding	NN	I-NP
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
was	was	VBD	0
smaller	smaller	JJR	0
than	than	IN	0
the	the	DT	0
change	change	NN	0
produced	produced	VBN	0
by	by	IN	0
piperazine	piperazine	JJ	B-NP
nitrogen	nitrogen	NN	I-NP
substitution	substitution	NN	I-NP
.	.	.	0
As	As	RB	0
described	described	VBN	0
below	below	RB	0
,	,	,	0
one	one	CD	0
candidate	candidate	NN	0
for	for	IN	0
this	this	DT	0
second	second	JJ	0
amino	amino	JJ	0
acid	acid	NN	B-NP
is	is	VBZ	0
Y152	Y152	CD	B-NP
.	.	.	0
y152	y152	NN	B-NP
functional	functional	JJ	I-NP
group	group	NN	I-NP
interaction	interaction	NN	I-NP
The	The	DT	0
Y152A	Y152A	NNP	0
mutation	mutation	VBD	0
produced	produced	VBN	B-NP
increase	increase	NN	I-NP
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NN	0
although	although	IN	0
the	the	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	B-NP
differed	differed	NN	I-NP
.	.	.	0
The	The	DT	0
increases	increases	NNS	0
in	in	IN	0
the	the	DT	0
K	K	NNP	0
i	i	FW	0
values	values	NNS	0
were	were	VBD	0
190	190	CD	0
fold	fold	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
98	98	CD	0
fold	fold	NN	0
for	for	IN	0
analog	analog	CD	0
1	1	CD	0
and	and	CC	0
only	only	RB	0
40	40	CD	0
fold	fold	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
analog	analog	CD	0
1	1	CD	0
retains	retains	VBZ	0
much	much	RB	0
of	of	IN	0
its	its	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
interact	interact	VB	0
with	with	IN	0
Y152	Y152	CD	B-NP
despite	despite	IN	0
the	the	DT	0
n-benzyl	n-benzyl	NN	B-NP
group	group	NN	I-NP
absence	absence	NN	I-NP
,	,	,	0
while	while	IN	0
analog	analog	CD	0
2	2	CD	0
interacts	interacts	NN	0
more	more	RBR	0
weakly	weakly	JJ	0
with	with	IN	0
this	this	DT	0
amino	amino	JJ	0
acid	acid	NN	B-NP
.	.	.	0
Since	Since	IN	0
the	the	DT	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
1	1	CD	0
is	is	VBZ	0
increased	increased	VBN	0
by	by	IN	0
the	the	DT	0
Y152A	Y152A	JJ	0
mutation	mutation	NN	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
unlikely	unlikely	JJ	0
that	that	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
interacts	interacts	NN	0
with	with	IN	0
Y152	Y152	CD	B-NP
.	.	.	0
The	The	DT	0
small	small	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
supports	supports	VBZ	0
a	a	DT	0
partial	partial	JJ	0
interaction	interaction	NN	0
of	of	IN	0
Y152	Y152	CD	B-NP
with	with	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
piperazine	piperazine	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
although	although	IN	0
some	some	DT	0
interaction	interaction	NN	0
with	with	IN	0
another	another	DT	0
group	group	NN	0
is	is	VBZ	0
also	also	RB	0
apparent	apparent	JJ	0
.	.	.	0
This	This	DT	0
other	other	JJ	0
group	group	NN	0
would	would	MD	0
be	be	VB	0
expected	expected	VBN	0
to	to	TO	0
be	be	VB	0
in	in	IN	0
close	close	JJ	0
proximity	proximity	NN	0
to	to	TO	0
the	the	DT	0
distal	distal	JJ	B-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
The	The	DT	0
most	most	RBS	0
likely	likely	JJ	0
candidate	candidate	NN	0
is	is	VBZ	0
the	the	DT	0
other	other	JJ	0
piperazine	piperazine	JJ	B-NP
ring	ring	NN	I-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
Thus	Thus	RB	0
Y152A	Y152A	CD	0
may	may	MD	0
form	form	VB	0
a	a	DT	0
partial	partial	JJ	0
interaction	interaction	NN	0
with	with	IN	0
both	both	DT	0
piperazine	piperazine	JJ	B-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
Conclusions	Conclusions	NNP	0
Figure	Figure	NNP	0
6shows	6shows	CD	0
a	a	DT	0
lerisetron-binding	lerisetron-binding	JJ	B-NP
site	site	NN	I-NP
hypothetical	hypothetical	JJ	I-NP
model	model	NN	I-NP
supported	supported	VBN	0
by	by	IN	0
our	our	PRP$	0
observation	observation	NN	B-NP
.	.	.	0
The	The	DT	0
model	model	NN	0
illustrates	illustrates	VBZ	0
the	the	DT	0
secondary	secondary	JJ	B-NP
structure	structure	NN	I-NP
of	of	IN	0
the	the	DT	0
region	region	NN	0
of	of	IN	0
the	the	DT	0
receptor	receptor	NN	B-NP
from	from	IN	0
Y140	Y140	CD	B-NP
-	-	:	0
Y152	Y152	CD	B-NP
in	in	IN	0
a	a	DT	0
loop	loop	JJ	0
configuration	configuration	NN	0
.	.	.	0
This	This	DT	0
structure	structure	NN	0
is	is	VBZ	0
supported	supported	VBN	0
by	by	IN	0
site-directed	site-directed	JJ	0
mutagenesis	mutagenesis	JJ	B-NP
data	data	NN	I-NP
[	[	-LRB-	0
25	25	CD	0
]	]	-RRB-	0
as	as	IN	0
well	well	RB	0
as	as	IN	0
structural	structural	JJ	B-NP
prediction	prediction	NN	I-NP
obtained	obtained	VBN	0
from	from	IN	0
other	other	JJ	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
31	31	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
recent	recent	JJ	0
determination	determination	NN	B-NP
of	of	IN	0
the	the	DT	0
structure	structure	NN	0
of	of	IN	0
a	a	DT	0
binding	binding	JJ	B-NP
protein	protein	NN	I-NP
nicotinic	nicotinic	NN	I-NP
acetylcholine	acetylcholine	NN	I-NP
[	[	-LRB-	0
27	27	CD	0
]	]	-RRB-	0
that	that	IN	0
shares	shares	NNS	0
significant	significant	JJ	0
homology	homology	NN	B-NP
with	with	IN	0
the	the	DT	0
LGIC	LGIC	NNP	B-NP
family	family	NN	I-NP
also	also	RB	0
supports	supports	VBZ	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
in	in	IN	0
this	this	DT	0
part	part	NN	0
of	of	IN	0
the	the	DT	0
protein	protein	NN	B-NP
.	.	.	0
The	The	DT	0
region	region	NN	0
from	from	IN	0
W89	W89	CD	B-NP
through	through	IN	0
Y93	Y93	NNP	B-NP
is	is	VBZ	0
shown	shown	VBN	0
as	as	IN	0
a	a	DT	0
β-sheet	β-sheet	JJ	B-NP
as	as	RB	0
has	has	VBZ	0
been	been	VBN	0
hypothesized	hypothesized	VBN	0
based	based	VBN	0
on	on	IN	0
site-directed	site-directed	JJ	0
mutagenesis	mutagenesis	JJ	B-NP
study	study	NN	I-NP
of	of	IN	0
this	this	DT	0
strand	strand	NN	0
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
Our	Our	PRP$	0
data	data	NNS	0
indicate	indicate	VBP	0
the	the	DT	0
lerisetron	lerisetron	NNS	B-NP
functional	functional	JJ	I-NP
group	group	NN	I-NP
that	that	WDT	0
may	may	MD	0
interact	interact	VB	0
with	with	IN	0
W89	W89	NNP	B-NP
,	,	,	0
R91	R91	NNP	B-NP
,	,	,	0
Y142	Y142	NNP	B-NP
and	and	CC	0
Y152	Y152	NNP	B-NP
.	.	.	0
W89	W89	NNP	B-NP
is	is	VBZ	0
shown	shown	VBN	0
interacting	interacting	VBN	0
with	with	IN	0
the	the	DT	0
lerisetron	lerisetron	NN	B-NP
aromatic	aromatic	JJ	I-NP
benzimidazole	benzimidazole	JJ	I-NP
group	group	NN	I-NP
although	although	IN	0
the	the	DT	0
precise	precise	JJ	0
position	position	NN	0
of	of	IN	0
W89	W89	CD	B-NP
relative	relative	JJ	I-NP
to	to	TO	0
this	this	DT	0
group	group	NN	0
is	is	VBZ	0
not	not	RB	0
known	known	VBN	0
.	.	.	0
The	The	DT	0
W89	W89	JJ	B-NP
interaction	interaction	NN	I-NP
with	with	IN	0
this	this	DT	0
group	group	NN	0
is	is	VBZ	0
supported	supported	VBN	0
by	by	IN	0
the	the	DT	0
observed	observed	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	B-NP
,	,	,	0
analog	analog	CD	0
1	1	CD	0
and	and	CC	0
analog	analog	CD	0
2	2	CD	0
.	.	.	0
Since	Since	IN	0
the	the	DT	0
benzimidazole	benzimidazole	JJ	B-NP
group	group	NN	I-NP
is	is	VBZ	0
common	common	JJ	0
to	to	TO	0
all	all	DT	0
three	three	CD	0
compounds	compounds	NN	0
it	it	PRP	0
is	is	VBZ	0
the	the	DT	0
most	most	RBS	0
likely	likely	JJ	0
point	point	NN	0
of	of	IN	0
interaction	interaction	NN	0
.	.	.	0
W89	W89	NNP	B-NP
also	also	RB	0
represents	represents	VBZ	0
a	a	DT	0
common	common	JJ	0
interaction	interaction	NN	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
for	for	IN	0
both	both	DT	0
lerisetron	lerisetron	NN	B-NP
and	and	CC	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
.	.	.	0
Y142	Y142	NNP	B-NP
is	is	VBZ	0
shown	shown	VBN	0
interacting	interacting	VBN	0
with	with	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
piperazina	piperazina	NN	I-NP
nitrogen	nitrogen	VBP	I-NP
possibly	possibly	RB	0
through	through	IN	0
a	a	DT	0
cation-π	cation-π	JJ	B-NP
interaction	interaction	NN	I-NP
.	.	.	0
This	This	DT	0
orientation	orientation	NN	0
of	of	IN	0
an	an	DT	0
amino	amino	JJ	0
group	group	NN	B-NP
interacting	interacting	NN	I-NP
with	with	IN	0
an	an	DT	0
aromatic	aromatic	JJ	B-NP
amino	amino	JJ	I-NP
acid	acid	NN	I-NP
in	in	IN	0
a	a	DT	0
cation-π	cation-π	JJ	B-NP
interaction	interaction	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
shown	shown	VBN	0
for	for	IN	0
the	the	DT	0
nicotinic	nicotinic	JJ	B-NP
acetylcholine	acetylcholine	JJ	I-NP
receptor	receptor	NN	I-NP
and	and	CC	0
has	has	VBZ	0
been	been	VBN	0
hypothesized	hypothesized	VBN	0
for	for	IN	0
many	many	JJ	0
lgic	lgic	NN	B-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
28	28	CD	0
29	29	CD	0
30	30	CD	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
This	This	DT	0
conclusion	conclusion	NN	0
is	is	VBZ	0
based	based	VBN	0
on	on	IN	0
both	both	PDT	0
the	the	DT	0
magnitude	magnitude	NN	0
of	of	IN	0
the	the	DT	0
change	change	NN	0
observed	observed	VBD	0
on	on	IN	0
the	the	DT	0
wild	wild	JJ	0
type	type	NN	B-NP
receptor	receptor	NN	I-NP
for	for	IN	0
removal	removal	NN	0
of	of	IN	0
the	the	DT	0
amino	amino	JJ	0
group	group	NN	0
(	(	-LRB-	0
400	400	CD	0
fold	fold	CD	0
)	)	-RRB-	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
effect	effect	NN	0
of	of	IN	0
the	the	DT	0
Y142A	Y142A	JJ	0
mutation	mutation	NN	0
on	on	IN	0
lerisetron	lerisetron	JJ	0
binding	binding	NNS	0
(	(	-LRB-	0
160	160	CD	0
fold	fold	CD	0
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
lack	lack	NN	0
of	of	IN	0
any	any	DT	0
major	major	JJ	0
change	change	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
as	as	IN	0
a	a	DT	0
result	result	NN	0
of	of	IN	0
this	this	DT	0
mutation	mutation	NN	0
.	.	.	0
Our	Our	PRP$	0
data	data	NN	0
does	does	VBZ	0
not	not	RB	0
support	support	VB	0
an	an	DT	0
interaction	interaction	NN	0
of	of	IN	0
this	this	DT	0
amino	amino	JJ	0
acid	acid	NN	B-NP
with	with	IN	0
either	either	RB	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
or	or	CC	0
lerisetron	lerisetron	NN	B-NP
benzimidazole	benzimidazole	JJ	I-NP
portion	portion	NN	I-NP
.	.	.	0
Y152	Y152	NNP	B-NP
is	is	VBZ	0
shown	shown	VBN	0
positioned	positioned	VBN	0
between	between	IN	0
the	the	DT	0
two	two	CD	0
piperazine	piperazine	CD	B-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
This	This	DT	0
conclusion	conclusion	NN	0
is	is	VBZ	0
supported	supported	VBN	0
by	by	IN	0
the	the	DT	0
smaller	smaller	JJR	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
(	(	-LRB-	0
40	40	CD	0
fold	fold	CD	0
)	)	-RRB-	0
compared	compared	VBN	0
to	to	TO	0
that	that	WDT	0
observed	observed	VBD	0
for	for	IN	0
lerisetron	lerisetron	NN	B-NP
(	(	-LRB-	0
190	190	CD	0
fold	fold	CD	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
results	results	NNS	0
suggest	suggest	VBP	0
a	a	DT	0
partial	partial	JJ	0
interaction	interaction	NN	0
of	of	IN	0
Y152	Y152	CD	B-NP
with	with	IN	0
the	the	DT	0
distal	distal	JJ	B-NP
piperazine	piperazine	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
.	.	.	0
Since	Since	IN	0
some	some	DT	0
change	change	NN	0
was	was	VBD	0
observed	observed	VBN	0
,	,	,	0
a	a	DT	0
second	second	JJ	0
interaction	interaction	NN	0
is	is	VBZ	0
also	also	RB	0
likely	likely	JJ	0
.	.	.	0
The	The	DT	0
functional	functional	JJ	B-NP
group	group	NN	I-NP
in	in	IN	0
closest	closest	JJS	0
proximity	proximity	NN	0
to	to	TO	0
the	the	DT	0
distal	distal	JJ	B-NP
piperazine	piperazine	JJ	I-NP
nitrogen	nitrogen	NN	I-NP
is	is	VBZ	0
the	the	DT	0
other	other	JJ	0
nitrogen	nitrogen	NN	B-NP
on	on	IN	0
the	the	DT	0
piperazine	piperazine	JJ	B-NP
ring	ring	NN	I-NP
.	.	.	0
Another	Another	DT	0
possibility	possibility	NN	0
would	would	MD	0
be	be	VB	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
interaction	interaction	NN	I-NP
,	,	,	0
however	however	RB	0
,	,	,	0
since	since	IN	0
the	the	DT	0
Y152A	Y152A	JJ	0
mutation	mutation	NN	0
also	also	RB	0
produced	produced	VBN	0
a	a	DT	0
large	large	JJ	0
increase	increase	NN	0
in	in	IN	0
K	K	NNP	0
i	i	NN	0
for	for	IN	0
analog	analog	CD	0
2	2	CD	0
,	,	,	0
this	this	DT	0
conclusion	conclusion	NN	0
is	is	VBZ	0
not	not	RB	0
supported	supported	VBN	0
by	by	IN	0
our	our	PRP$	0
data	data	NNS	0
.	.	.	0
R91	R91	NNP	B-NP
is	is	VBZ	0
shown	shown	VBN	0
as	as	IN	0
interacting	interacting	NN	0
with	with	IN	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
This	This	DT	0
is	is	VBZ	0
a	a	DT	0
difficult	difficult	JJ	0
conclusion	conclusion	NN	0
to	to	TO	0
make	make	VB	0
considering	considering	VBG	0
the	the	DT	0
small	small	JJ	0
effect	effect	NN	0
of	of	IN	0
the	the	DT	0
R91A	R91A	JJ	0
mutation	mutation	NN	0
on	on	IN	0
lerisetron	lerisetron	JJ	B-NP
binding	binding	NN	I-NP
.	.	.	0
The	The	DT	0
interaction	interaction	NN	0
is	is	VBZ	0
included	included	VBN	0
in	in	IN	0
the	the	DT	0
model	model	NN	0
based	based	VBN	0
on	on	IN	0
structural	structural	JJ	B-NP
information	information	NN	I-NP
obtained	obtained	VBN	0
from	from	IN	0
the	the	DT	0
crystal	crystal	NN	0
structure	structure	NN	0
of	of	IN	0
AChBP	AChBP	NNP	B-NP
[	[	-LRB-	0
27	27	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
region	region	NN	0
of	of	IN	0
this	this	DT	0
protein	protein	NN	B-NP
homologous	homologous	NN	I-NP
to	to	TO	0
loop	loop	VB	0
E	E	NN	0
and	and	CC	0
loop	loop	JJ	0
D	D	NNP	0
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3A	3A	CD	0
receptor	receptor	NN	0
suggests	suggests	VBZ	0
a	a	DT	0
loop	loop	JJ	0
structure	structure	NN	0
from	from	IN	0
Y140	Y140	CD	B-NP
to	to	TO	0
Y152	Y152	CD	B-NP
and	and	CC	0
a	a	DT	0
3-residue	3-residue	NNP	0
turn	turn	VBP	0
containing	containing	VBG	0
a	a	DT	0
glycine	glycine	NN	B-NP
at	at	IN	0
position	position	NN	0
147	147	CD	0
and	and	CC	0
the	the	DT	0
β-strand	β-strand	JJ	B-NP
from	from	IN	0
W89	W89	CD	B-NP
through	through	IN	0
Y93	Y93	CD	B-NP
oriented	oriented	VBN	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
Figure	Figure	NNP	0
6	6	CD	0
.	.	.	0
The	The	DT	0
orientation	orientation	NN	0
of	of	IN	0
lerisetron	lerisetron	NN	B-NP
between	between	IN	0
W89	W89	NNP	B-NP
and	and	CC	0
Y142A	Y142A	NNP	0
as	as	RB	0
shown	shown	VBN	0
would	would	MD	0
enable	enable	VB	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
to	to	TO	0
be	be	VB	0
positioned	positioned	VBN	0
in	in	IN	0
close	close	JJ	0
proximity	proximity	NN	0
to	to	TO	0
R91	R91	CD	B-NP
.	.	.	0
If	If	IN	0
this	this	DT	0
is	is	VBZ	0
the	the	DT	0
case	case	NN	0
,	,	,	0
then	then	RB	0
a	a	DT	0
small	small	JJ	0
alteration	alteration	NN	0
in	in	IN	0
position	position	NN	0
of	of	IN	0
analog	analog	CD	0
1	1	CD	0
or	or	CC	0
2	2	CD	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
could	could	MD	0
result	result	VB	0
in	in	IN	0
the	the	DT	0
loss	loss	NN	0
of	of	IN	0
this	this	DT	0
presumably	presumably	RB	0
weak	weak	JJ	0
interaction	interaction	NN	0
.	.	.	0
The	The	DT	0
apparent	apparent	JJ	0
alterations	alterations	NN	0
in	in	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
location	location	NN	0
of	of	IN	0
analog	analog	CD	0
1	1	CD	0
would	would	MD	0
be	be	VB	0
consistent	consistent	JJ	0
with	with	IN	0
this	this	DT	0
hypothesis	hypothesis	NN	0
.	.	.	0
An	An	DT	0
alternate	alternate	JJ	0
hypothesis	hypothesis	NN	0
would	would	MD	0
place	place	VB	0
the	the	DT	0
N-benzyl	N-benzyl	JJ	B-NP
group	group	NN	I-NP
in	in	IN	0
a	a	DT	0
different	different	JJ	0
position	position	NN	0
,	,	,	0
interacting	interacting	VBG	0
with	with	IN	0
another	another	DT	0
amino	amino	JJ	0
acid	acid	NN	B-NP
;	;	:	0
either	either	CC	0
solely	solely	RB	0
or	or	CC	0
in	in	IN	0
concert	concert	NN	0
with	with	IN	0
R91	R91	CD	B-NP
.	.	.	0
Our	Our	PRP$	0
data	data	NNS	0
support	support	VBP	0
a	a	DT	0
binding	binding	JJ	0
site	site	NN	0
for	for	IN	0
lerisetron	lerisetron	NN	0
on	on	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
that	that	IN	0
spans	spans	VBG	0
the	the	DT	0
D	D	NNP	0
and	and	CC	0
E	E	NN	0
loop	loop	NN	0
regions	regions	NNS	0
.	.	.	0
Table	Table	NN	0
2shows	2shows	VBZ	0
the	the	DT	0
sequence	sequence	JJ	B-NP
alignment	alignment	NN	I-NP
for	for	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
R	R	NN	0
,	,	,	0
the	the	DT	0
α7	α7	JJ	0
receptor	receptor	NN	0
and	and	CC	0
the	the	DT	0
AChBP	AChBP	JJ	0
for	for	IN	0
these	these	DT	0
loops	loops	NNS	0
.	.	.	0
Sequence	Sequence	JJ	B-NP
alignment	alignment	NN	I-NP
of	of	IN	0
mouse	mouse	CD	0
5-HT	5-HT	CD	0
3	3	CD	0
AR	AR	NNP	B-NP
,	,	,	0
α7	α7	NNP	0
nAchR	nAchR	NNP	0
and	and	CC	0
AChBP	AChBP	JJ	B-NP
result	result	NN	I-NP
in	in	IN	0
alignment	alignment	NN	0
of	of	IN	0
the	the	DT	0
proposed	proposed	JJ	0
D	D	NNP	0
and	and	CC	0
E	E	NN	B-NP
loop	loop	NN	I-NP
of	of	IN	0
the	the	DT	0
5-HT	5-HT	CD	0
3	3	CD	0
AR	AR	NN	B-NP
with	with	IN	0
corresponding	corresponding	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
α7	α7	NNP	0
nAchR	nAchR	NNP	0
and	and	CC	0
AChBP	AChBP	JJ	0
.	.	.	0
The	The	DT	0
amino	amino	JJ	0
acids	acids	JJ	0
W89	W89	NN	B-NP
,	,	,	0
R91	R91	NNP	B-NP
Y140	Y140	NNP	I-NP
,	,	,	0
Y142	Y142	NNP	B-NP
and	and	CC	0
5ht	5ht	NN	B-NP
y152	y152	NN	I-NP
3	3	CD	0
A	A	DT	0
R	R	NN	0
can	can	MD	0
be	be	VB	0
aligned	aligned	VBN	0
with	with	IN	0
W53	W53	NNP	B-NP
,	,	,	0
Q55	Q55	NNP	B-NP
,	,	,	0
L102	L102	NNP	B-NP
,	,	,	0
R104	R104	NNP	B-NP
,	,	,	0
and	and	CC	0
M114	M114	CD	B-NP
of	of	IN	0
the	the	DT	0
AChBP	AChBP	JJ	0
(	(	-LRB-	0
Figure	Figure	NNP	0
6	6	CD	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
amino	amino	JJ	0
acids	acids	NNS	0
form	form	VBP	0
a	a	DT	0
cluster	cluster	NN	0
in	in	IN	0
the	the	DT	0
proposed	proposed	JJ	0
acetylcholine	acetylcholine	JJ	B-NP
binding	binding	JJ	I-NP
domain	domain	NN	I-NP
of	of	IN	0
AChBP	AChBP	JJ	0
similar	similar	JJ	0
to	to	TO	0
that	that	DT	0
proposed	proposed	VBN	0
in	in	IN	0
our	our	PRP$	0
model	model	NN	0
.	.	.	0
Both	Both	DT	0
loops	loops	NNS	0
have	have	VBP	0
been	been	VBN	0
identified	identified	VBN	0
on	on	IN	0
the	the	DT	0
complementary	complementary	JJ	B-NP
face	face	NN	I-NP
of	of	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
of	of	IN	0
the	the	DT	0
nAChR	nAChR	JJ	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
unknown	unknown	VBN	B-NP
if	if	IN	0
lerisetron	lerisetron	JJ	0
utilizes	utilizes	JJ	0
amino	amino	JJ	0
acids	acids	NNS	0
on	on	IN	0
the	the	DT	0
principal	principal	JJ	B-NP
face	face	NN	I-NP
although	although	IN	0
none	none	NN	0
have	have	VBP	0
been	been	VBN	0
identified	identified	VBN	0
.	.	.	0
The	The	DT	0
model	model	NN	0
for	for	IN	0
lerisetron	lerisetron	JJ	B-NP
binding	binding	NN	I-NP
will	will	MD	0
be	be	VB	0
further	further	RB	0
refined	refined	VBN	0
as	as	IN	0
its	its	PRP$	0
interaction	interaction	NN	B-NP
with	with	IN	0
other	other	JJ	0
binding	binding	JJ	0
site	site	NN	0
amino	amino	NN	0
acids	acids	NNS	0
are	are	VBP	0
investigated	investigated	VBN	0
[	[	-LRB-	0
26	26	CD	0
32	32	CD	0
33	33	CD	0
]	]	-RRB-	0
.	.	.	0
Of	Of	IN	0
particular	particular	JJ	0
interest	interest	NN	0
would	would	MD	0
be	be	VB	0
n-benzyl	n-benzyl	NN	B-NP
group	group	NN	I-NP
potential	potential	JJ	I-NP
interaction	interaction	NN	I-NP
that	that	WDT	0
would	would	MD	0
account	account	VB	0
for	for	IN	0
the	the	DT	0
decrease	decrease	NN	0
in	in	IN	0
binding	binding	JJ	0
affinity	affinity	NN	B-NP
of	of	IN	0
analog	analog	CD	0
2	2	CD	0
.	.	.	0
Additional	Additional	JJ	B-NP
information	information	NN	I-NP
gained	gained	VBD	0
from	from	IN	0
comparison	comparison	NN	0
of	of	IN	0
our	our	PRP$	0
model	model	NN	0
with	with	IN	0
the	the	DT	0
recent	recent	JJ	0
crystal	crystal	NN	0
structure	structure	NN	0
of	of	IN	0
the	the	DT	0
AChBP	AChBP	JJ	0
demonstrates	demonstrates	NN	0
that	that	IN	0
lerisetron	lerisetron	NN	B-NP
can	can	MD	0
be	be	VB	0
roughly	roughly	RB	0
'	'	POS	0
fit	fit	NN	0
'	'	''	0
into	into	IN	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
such	such	JJ	0
that	that	IN	0
all	all	PDT	0
the	the	DT	0
residues	residues	JJ	B-NP
line	line	NN	I-NP
up	up	RB	0
as	as	RB	0
shown	shown	VBN	0
in	in	IN	0
our	our	PRP$	0
model	model	NN	0
.	.	.	0
While	While	IN	0
this	this	DT	0
is	is	VBZ	0
not	not	RB	0
direct	direct	JJ	0
evidence	evidence	NN	0
that	that	IN	0
the	the	DT	0
model	model	NN	0
is	is	VBZ	0
correct	correct	JJ	0
,	,	,	0
subsequent	subsequent	JJ	0
molecular	molecular	JJ	B-NP
modeling	modeling	NN	I-NP
of	of	IN	0
the	the	DT	0
data	data	NNS	0
presented	presented	VBN	0
in	in	IN	0
this	this	DT	0
paper	paper	NN	0
may	may	MD	0
provide	provide	VB	0
further	further	JJ	0
support	support	NN	0
for	for	IN	0
our	our	PRP$	0
hypothesis	hypothesis	NN	0
.	.	.	0
Our	Our	PRP$	0
current	current	JJ	0
model	model	NN	0
provides	provides	VBZ	0
an	an	DT	0
initial	initial	JJ	0
working	working	NN	B-NP
hypothesis	hypothesis	NN	I-NP
that	that	WDT	0
can	can	MD	0
form	form	VB	0
the	the	DT	0
basis	basis	NN	0
of	of	IN	0
further	further	JJ	0
investigation	investigation	NN	B-NP
.	.	.	0
Also	Also	RB	0
,	,	,	0
while	while	IN	0
it	it	PRP	0
is	is	VBZ	0
unclear	unclear	JJ	0
whether	whether	IN	0
the	the	DT	0
information	information	NN	0
obtained	obtained	VBN	0
in	in	IN	0
this	this	DT	0
study	study	NN	0
can	can	MD	0
be	be	VB	0
extended	extended	VBN	0
to	to	TO	0
other	other	JJ	0
5-HT	5-HT	CD	0
3	3	CD	0
r	r	NN	B-NP
ligand	ligand	NN	I-NP
,	,	,	0
a	a	DT	0
similar	similar	JJ	0
approach	approach	NN	0
would	would	MD	0
be	be	VB	0
useful	useful	JJ	0
in	in	IN	0
identifying	identifying	VBG	0
mcpbg	mcpbg	NN	B-NP
functional	functional	JJ	I-NP
group	group	NN	I-NP
interaction	interaction	NN	I-NP
,	,	,	0
5-HT	5-HT	NNP	0
,	,	,	0
dtC	dtC	JJ	0
and	and	CC	0
granisetron	granisetron	NN	B-NP
.	.	.	0
Materials	Materials	NNS	0
and	and	CC	0
Methods	Methods	NNP	0
Mutagenesis	Mutagenesis	NNP	0
Wild	Wild	NNP	0
type	type	FW	0
5-HT	5-HT	FW	0
3AS	3AS	FW	0
mouse	mouse	FW	0
receptor	receptor	FW	0
cDNA	cDNA	NNP	0
was	was	VBD	0
derived	derived	VBN	0
from	from	IN	0
N1E-115	N1E-115	CD	0
neuroblastoma	neuroblastoma	CD	0
cells	cells	NNS	0
as	as	IN	0
previously	previously	RB	0
described	described	VBN	0
[	[	-LRB-	0
24	24	CD	0
]	]	-RRB-	0
.	.	.	0
Mutant	Mutant	JJ	0
receptors	receptors	NNS	0
were	were	VBD	0
constructed	constructed	VBN	0
using	using	VBG	0
polymerase	polymerase	JJ	0
chain	chain	NN	0
reaction	reaction	NN	0
(	(	-LRB-	0
Quick	Quick	RB	0
change	change	VB	0
mutagenesis	mutagenesis	JJ	0
kit	kit	NN	0
,	,	,	0
Promega	Promega	NNP	0
)	)	-RRB-	0
.	.	.	0
All	All	DT	0
mutations	mutations	NN	0
were	were	VBD	0
confirmed	confirmed	VBN	0
by	by	IN	0
DNA	DNA	NNP	0
sequencing	sequencing	NN	0
.	.	.	0
Cell	Cell	NN	0
culture	culture	NN	0
methods	methods	NNS	0
and	and	CC	0
tsa201	tsa201	NN	B-NP
cell	cell	NN	I-NP
transfection	transfection	NN	I-NP
(	(	-LRB-	0
a	a	DT	0
hek293	hek293	NN	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
derivative	derivative	JJ	I-NP
)	)	-RRB-	0
were	were	VBD	0
grown	grown	VBN	0
in	in	IN	0
Dulbecco	Dulbecco	NNP	0
's	's	POS	0
modified	modified	JJ	0
Eagles	Eagles	JJ	0
medium	medium	NN	0
(	(	-LRB-	0
D-MEM	D-MEM	NNP	0
)	)	-RRB-	0
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
fetal	fetal	JJ	B-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
bovine	bovine	JJ	I-NP
serum	serum	NN	I-NP
and	and	CC	0
100-units	100-units	FW	0
/	/	FW	0
ml	ml	FW	0
penicillin	penicillin	FW	0
/	/	FW	0
streptomycin	streptomycin	FW	0
.	.	.	0
Cultures	Cultures	NNS	0
were	were	VBD	0
maintained	maintained	VBN	0
in	in	IN	0
humidified	humidified	JJ	0
atmosphere	atmosphere	NN	B-NP
of	of	IN	0
5	5	CD	0
%	%	NN	0
CO	CO	NNP	0
2	2	CD	0
at	at	IN	0
37°C	37°C	CD	0
.	.	.	0
For	For	IN	0
binding	binding	JJ	0
studies	studies	NNS	0
,	,	,	0
tsa201	tsa201	NN	B-NP
cell	cell	NN	I-NP
were	were	VBD	0
plated	plated	VBN	0
at	at	IN	0
a	a	DT	0
density	density	NN	0
of	of	IN	0
5	5	CD	0
×	×	CD	0
10	10	CD	0
6cells	6cells	CD	0
/	/	CD	0
75	75	CD	0
cm	cm	NNS	0
2and	2and	VBP	0
grown	grown	VBN	0
for	for	IN	0
9	9	CD	0
hours	hours	NNS	0
prior	prior	RB	0
to	to	TO	0
transfection	transfection	VB	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
transfected	transfected	VBN	0
with	with	IN	0
10	10	CD	0
μg	μg	FW	0
murine	murine	FW	0
5-HT	5-HT	FW	0
3AS	3AS	FW	0
R	R	FW	0
cDNA	cDNA	FW	0
using	using	FW	0
calcium	calcium	NN	B-NP
phosphate	phosphate	NN	I-NP
co-precipitation	co-precipitation	NN	I-NP
(	(	-LRB-	0
New	New	NNP	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
,	,	,	0
NY	NY	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
then	then	RB	0
incubated	incubated	CD	0
36	36	CD	0
hours	hours	NNS	0
prior	prior	RB	0
to	to	TO	0
harvesting	harvesting	VB	0
.	.	.	0
For	For	IN	0
whole	whole	JJ	0
cell	cell	NN	0
patch	patch	NN	0
clamp	clamp	NN	0
experiments	experiments	NNS	0
,	,	,	0
tsa201	tsa201	NN	B-NP
cell	cell	NN	I-NP
were	were	VBD	0
plated	plated	VBN	0
at	at	IN	0
a	a	DT	0
density	density	NN	0
of	of	IN	0
0.25	0.25	CD	0
×	×	CD	0
10	10	CD	0
6cells	6cells	CD	0
/	/	CD	0
27	27	CD	0
cm	cm	CD	0
2dish	2dish	CD	0
and	and	CC	0
grown	grown	VBN	0
12	12	CD	0
hours	hours	NNS	0
prior	prior	RB	0
to	to	TO	0
transfection	transfection	VB	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
washed	washed	VBN	0
with	with	IN	0
fresh	fresh	JJ	0
culture	culture	NN	0
medium	medium	NN	0
then	then	RB	0
transfected	transfected	VBN	0
with	with	IN	0
10	10	CD	0
μg	μg	CD	0
5-HT	5-HT	CD	0
3AS	3AS	CD	0
R	R	NN	0
cDNA	cDNA	NN	0
using	using	VBG	0
Qiagen	Qiagen	NNP	B-NP
Superfect	Superfect	NNP	I-NP
transfection	transfection	NN	I-NP
reagent	reagent	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
,	,	,	0
CA	CA	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
transfected	transfected	NN	B-NP
cell	cell	NN	I-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
this	this	DT	0
mixture	mixture	NN	0
for	for	IN	0
2.5	2.5	CD	0
hours	hours	NNS	0
,	,	,	0
then	then	RB	0
divided	divided	VBN	0
into	into	IN	0
35	35	CD	0
mm	mm	JJ	0
culture	culture	NN	0
dishes	dishes	NNS	0
at	at	IN	0
a	a	DT	0
density	density	NN	0
of	of	IN	0
approximately	approximately	RB	0
5	5	CD	0
×	×	CD	0
10	10	CD	0
4cells	4cells	CD	0
/	/	CD	0
dish	dish	NN	0
and	and	CC	0
incubated	incubated	NN	0
for	for	IN	0
24	24	CD	0
hours	hours	NNS	0
at	at	IN	0
37°C	37°C	CD	0
before	before	IN	0
recording	recording	NN	0
.	.	.	0
binding	binding	JJ	B-NP
assay	assay	NN	I-NP
transfected	transfected	NN	I-NP
cell	cell	NN	I-NP
radioligand	radioligand	NN	I-NP
were	were	VBD	0
scraped	scraped	VBN	0
from	from	IN	0
the	the	DT	0
dishes	dishes	NNS	0
,	,	,	0
washed	washed	VBD	0
twice	twice	RB	0
with	with	IN	0
Dulbecco	Dulbecco	NNP	0
's	's	POS	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
(	(	-LRB-	0
New	New	NNP	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
,	,	,	0
NY	NY	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
then	then	RB	0
resuspended	resuspended	VBN	0
in	in	IN	0
1.0	1.0	CD	0
ml	ml	JJ	B-NP
pb	pb	NN	I-NP
/	/	CD	0
100	100	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
either	either	RB	0
used	used	VBN	0
fresh	fresh	JJ	0
or	or	CC	0
frozen	frozen	VBN	0
at	at	IN	0
this	this	DT	0
step	step	NN	0
until	until	IN	0
needed	needed	VBN	0
.	.	.	0
Immediately	Immediately	RB	0
prior	prior	RB	0
to	to	TO	0
use	use	VB	0
,	,	,	0
cells	cells	NNS	0
were	were	VBD	0
homogenized	homogenized	VBN	B-NP
in	in	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
using	using	VBG	0
a	a	DT	0
glass	glass	NN	0
tissue	tissue	NN	0
homogenizer	homogenizer	VBZ	0
then	then	RB	0
centrifuged	centrifuged	VBN	0
at	at	IN	0
35	35	CD	0
000	000	CD	0
×	×	CD	0
g	g	NN	0
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
in	in	IN	0
a	a	DT	0
Beckman	Beckman	NNP	B-NP
JA20	JA20	NNP	I-NP
rotor	rotor	NN	I-NP
.	.	.	0
Membranes	Membranes	NNP	0
were	were	VBD	0
washed	washed	VBN	0
once	once	RB	0
more	more	JJR	0
with	with	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
then	then	RB	0
resuspended	resuspended	VBN	0
in	in	IN	0
1	1	CD	0
ml	ml	JJ	B-NP
pb	pb	NN	I-NP
/	/	CD	0
100	100	CD	0
mm	mm	JJ	0
dish	dish	NN	0
.	.	.	0
Protein	Protein	NN	B-NP
content	content	NN	I-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
a	a	DT	0
Lowry	Lowry	JJ	B-NP
assay	assay	NN	I-NP
(	(	-LRB-	0
Sigma	Sigma	NNP	B-NP
.	.	.	0
Diagnostics	Diagnostics	NNP	0
,	,	,	0
St.	St.	NNP	B-NP
Louis	Louis	NNP	0
,	,	,	0
MO	MO	NNP	0
)	)	-RRB-	0
.	.	.	0
Binding	Binding	JJ	0
assays	assays	NN	0
were	were	VBD	0
performed	performed	VBN	0
in	in	IN	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
.	.	.	0
For	For	IN	0
K	K	NNP	0
d	d	SYM	0
determination	determination	NN	B-NP
,	,	,	0
100	100	CD	0
homogenate	homogenate	NN	B-NP
μl	μl	NN	I-NP
was	was	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
1	1	CD	0
hour	hour	NN	0
with	with	IN	0
varying	varying	VBG	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
(	(	-LRB-	0
NEN	NEN	NNP	B-NP
,	,	,	0
MA	MA	NNP	0
)	)	-RRB-	0
.	.	.	0
Specific	Specific	JJ	0
binding	binding	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
was	was	VBD	0
determined	determined	VBN	0
as	as	IN	0
the	the	DT	0
bound	bound	NN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
not	not	RB	0
displaced	displaced	VBN	0
by	by	IN	0
a	a	DT	0
saturating	saturating	JJ	0
concentration	concentration	NN	B-NP
of	of	IN	0
a	a	DT	0
competing	competing	JJ	0
ligand	ligand	NN	B-NP
(	(	-LRB-	0
100	100	CD	0
μM	μM	JJ	B-NP
mCPBG	mCPBG	JJ	I-NP
or	or	CC	0
10	10	CD	0
μM	μM	JJ	B-NP
MDL-72222	MDL-72222	CD	I-NP
)	)	-RRB-	0
.	.	.	0
K	K	NNP	0
d	d	NN	0
values	values	NNS	0
were	were	VBD	0
determined	determined	VBN	0
by	by	IN	0
fitting	fitting	VBG	0
the	the	DT	0
binding	binding	JJ	0
data	data	NNS	0
to	to	TO	0
the	the	DT	0
following	following	JJ	0
equation	equation	NN	0
using	using	VBG	0
GraphPad	GraphPad	JJ	B-NP
PRISM	PRISM	NNP	I-NP
(	(	-LRB-	0
San	San	NNP	B-NP
Diego	Diego	NNP	I-NP
CA	CA	NNP	I-NP
)	)	-RRB-	0
:	:	:	0
B	B	NNP	0
=	=	NNP	0
Bmax	Bmax	NNP	B-NP
[	[	-LRB-	0
L	L	NNP	0
]	]	-RRB-	0
n	n	FW	0
/	/	FW	0
(	(	-LRB-	0
[	[	-LRB-	0
L	L	NNP	0
]	]	-RRB-	0
n	n	FW	0
+	+	FW	0
Kn	Kn	NN	B-NP
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
θ	θ	NN	0
is	is	VBZ	0
bound	bound	VBN	0
ligand	ligand	NN	B-NP
,	,	,	0
Bmax	Bmax	NNP	B-NP
is	is	VBZ	0
the	the	DT	0
maximum	maximum	JJ	0
binding	binding	NN	0
at	at	IN	0
equilibrium	equilibrium	JJ	B-NP
L	L	NNP	I-NP
is	is	VBZ	0
the	the	DT	0
free	free	JJ	0
ligand	ligand	JJ	B-NP
concentration	concentration	NN	I-NP
and	and	CC	0
n	n	NN	0
is	is	VBZ	0
the	the	DT	0
Hill	Hill	NNP	0
coefficient	coefficient	NN	0
.	.	.	0
For	For	IN	0
K	K	NNP	0
i	i	FW	0
determination	determination	NN	B-NP
,	,	,	0
100	100	CD	0
homogenate	homogenate	NN	B-NP
μl	μl	NN	I-NP
was	was	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37°C	37°C	CD	0
for	for	IN	0
2	2	CD	0
hours	hours	NNS	0
with	with	IN	0
varying	varying	VBG	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
inhibitor	inhibitor	NN	0
and	and	CC	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	NN	B-NP
(	(	-LRB-	0
NEN	NEN	NNP	B-NP
,	,	,	0
MA	MA	NNP	0
)	)	-RRB-	0
.	.	.	0
Binding	Binding	NNP	0
was	was	VBD	0
terminated	terminated	VBN	0
by	by	IN	0
rapid	rapid	JJ	B-NP
filtration	filtration	NN	I-NP
onto	onto	IN	0
a	a	DT	0
gf/b	gf/b	NN	B-NP
filter	filter	NN	I-NP
.	.	.	0
The	The	DT	0
IC	IC	NNP	B-NP
50	50	CD	0
values	values	NNS	0
were	were	VBD	0
calculated	calculated	VBN	0
by	by	IN	0
fitting	fitting	VBG	0
the	the	DT	0
data	data	NNS	0
to	to	TO	0
the	the	DT	0
following	following	JJ	0
equation	equation	NN	0
using	using	VBG	0
GraphPad	GraphPad	JJ	B-NP
PRISM	PRISM	NNP	I-NP
(	(	-LRB-	0
San	San	NNP	B-NP
Diego	Diego	NNP	I-NP
CA	CA	NNP	I-NP
)	)	-RRB-	0
:	:	:	0
θ	θ	CD	0
=	=	SYM	0
1	1	CD	0
/	/	CD	0
(	(	-LRB-	0
1+	1+	NNP	0
(	(	-LRB-	0
L	L	NNP	0
/	/	NNP	0
IC	IC	NNP	0
50	50	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
θ	θ	NN	0
is	is	VBZ	0
the	the	DT	0
fractional	fractional	JJ	B-NP
amount	amount	NN	I-NP
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
bound	bound	VBN	0
in	in	IN	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
inhibitor	inhibitor	NN	0
at	at	IN	0
concentration	concentration	NN	B-NP
L	L	NNP	I-NP
as	as	RB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
amount	amount	NN	0
of	of	IN	0
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
granisetron	granisetron	VBZ	0
bound	bound	VBN	0
in	in	IN	0
the	the	DT	0
absence	absence	NN	B-NP
of	of	IN	0
inhibitor	inhibitor	NN	0
.	.	.	0
IC	IC	NNP	B-NP
50	50	CD	0
is	is	VBZ	0
the	the	DT	0
concentration	concentration	NN	B-NP
at	at	IN	0
which	which	WDT	0
θ	θ	VBD	0
=	=	CD	0
0.5	0.5	CD	0
.	.	.	0
The	The	DT	0
K	K	NNP	0
i	i	FW	0
is	is	VBZ	0
calculated	calculated	VBN	0
from	from	IN	0
the	the	DT	0
IC	IC	NNP	B-NP
50	50	CD	0
value	value	NN	0
using	using	VBG	0
the	the	DT	0
Cheng-Prusoff	Cheng-Prusoff	JJ	B-NP
equation	equation	NN	I-NP
.	.	.	0
transfected	transfected	NN	B-NP
tsa201	tsa201	NN	I-NP
cell	cell	NN	I-NP
electrophysiological	electrophysiological	NN	I-NP
method	method	NN	I-NP
were	were	VBD	0
transferred	transferred	VBN	0
to	to	TO	0
a	a	DT	0
recording	recording	NN	B-NP
chamber	chamber	NN	I-NP
and	and	CC	0
submerged	submerged	NN	0
in	in	IN	0
extracellular	extracellular	JJ	B-NP
recording	recording	NN	I-NP
buffer	buffer	NN	I-NP
containing	containing	VBG	0
25	25	CD	0
ph	ph	NN	B-NP
mm	mm	NN	I-NP
hepe	hepe	NN	I-NP
7.4	7.4	CD	0
,	,	,	0
140	140	CD	0
mM	mM	JJ	B-NP
NaCl	NaCl	NN	I-NP
,	,	,	0
1.7	1.7	CD	0
mM	mM	JJ	0
MgCl	MgCl	JJ	B-NP
2	2	CD	0
,	,	,	0
5	5	CD	0
mM	mM	JJ	B-NP
KCl	KCl	NN	I-NP
,	,	,	0
1.8	1.8	CD	0
mM	mM	JJ	0
CaCl	CaCl	JJ	B-NP
2	2	CD	0
.	.	.	0
Patch	Patch	JJ	0
electrodes	electrodes	NNS	0
(	(	-LRB-	0
2-2.5	2-2.5	NNP	0
MΩ	MΩ	NNP	B-NP
)	)	-RRB-	0
were	were	VBD	0
filled	filled	VBN	0
with	with	IN	0
intracellular	intracellular	JJ	B-NP
recording	recording	NN	I-NP
buffer	buffer	NN	I-NP
containing	containing	VBG	0
25	25	CD	0
ph	ph	NN	B-NP
mm	mm	NN	I-NP
hepe	hepe	NN	I-NP
7.4	7.4	CD	0
,	,	,	0
145	145	CD	0
mM	mM	JJ	B-NP
KCL	KCL	NNP	I-NP
,	,	,	0
2	2	CD	0
mM	mM	JJ	0
MgCl	MgCl	JJ	B-NP
2	2	CD	0
and	and	CC	0
1	1	CD	0
mM	mM	JJ	B-NP
EGTA	EGTA	NNP	I-NP
.	.	.	0
Cells	Cells	NNS	0
were	were	VBD	0
clamped	clamped	VBN	0
in	in	IN	0
whole	whole	JJ	0
cell	cell	NN	0
configuration	configuration	NN	0
at	at	IN	0
a	a	DT	0
holding	holding	NN	B-NP
potential	potential	NN	I-NP
of	of	IN	0
-60	-60	NNP	0
mV	mV	NNP	0
.	.	.	0
Currents	Currents	JJ	0
elicited	elicited	NN	0
by	by	IN	0
agonist	agonist	JJ	B-NP
application	application	NN	I-NP
were	were	VBD	0
measured	measured	VBN	0
using	using	VBG	0
an	an	DT	0
Axopatch	Axopatch	NNP	0
200B	200B	FW	0
amplifier	amplifier	FW	0
(	(	-LRB-	0
Foster	Foster	NNP	0
City	City	NNP	0
,	,	,	0
CA	CA	NNP	B-NP
)	)	-RRB-	0
under	under	IN	0
computer	computer	NN	B-NP
control	control	NN	I-NP
(	(	-LRB-	0
DataPac	DataPac	NNP	B-NP
2000	2000	CD	0
,	,	,	0
RUN	RUN	NNP	0
Technologies	Technologies	NNPS	0
)	)	-RRB-	0
.	.	.	0
agonist	agonist	NN	B-NP
and	and	CC	0
antagonists	antagonists	NNS	0
were	were	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
extracellular	extracellular	JJ	B-NP
solution	solution	NN	I-NP
and	and	CC	0
delivered	delivered	VBN	0
to	to	TO	0
cells	cells	NNS	0
using	using	VBG	0
a	a	DT	0
rapid	rapid	JJ	B-NP
perfusion	perfusion	JJ	I-NP
system	system	NN	I-NP
(	(	-LRB-	0
Warner	Warner	NNP	0
Instruments	Instruments	NNP	0
,	,	,	0
Hamden	Hamden	NNP	0
,	,	,	0
CT	CT	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
For	For	IN	0
EC	EC	NNP	B-NP
50	50	CD	0
determination	determination	NN	B-NP
,	,	,	0
responses	responses	NNS	0
were	were	VBD	0
normalized	normalized	VBN	0
to	to	TO	0
the	the	DT	0
maximum	maximum	JJ	0
response	response	NN	0
obtained	obtained	VBN	0
from	from	IN	0
the	the	DT	0
full	full	JJ	0
agonist	agonist	JJ	0
5-HT	5-HT	NN	0
and	and	CC	0
fitted	fitted	JJ	0
to	to	TO	0
the	the	DT	0
equation	equation	NN	0
Ψ=	Ψ=	CD	0
1	1	CD	0
/	/	CD	0
1+	1+	CD	0
(	(	-LRB-	0
EC50	EC50	NNP	0
/	/	NNP	0
[	[	-LRB-	0
C	C	NNP	0
]	]	-RRB-	0
n	n	NN	0
)	)	-RRB-	0
,	,	,	0
where	where	WRB	0
Ψ	Ψ	NNP	0
is	is	VBZ	0
the	the	DT	0
normalized	normalized	JJ	0
current	current	JJ	0
at	at	IN	0
5-HT	5-HT	CD	0
concentration	concentration	NN	0
[	[	-LRB-	0
C	C	NNP	0
]	]	-RRB-	0
,	,	,	0
EC50	EC50	NNP	B-NP
is	is	VBZ	0
the	the	DT	0
concentration	concentration	NN	B-NP
of	of	IN	0
5-HT	5-HT	NNP	0
needed	needed	VBD	0
to	to	TO	0
obtain	obtain	VB	0
half	half	DT	0
maximal	maximal	JJ	B-NP
activation	activation	NN	I-NP
and	and	CC	0
n	n	NN	0
is	is	VBZ	0
the	the	DT	0
apparent	apparent	JJ	0
Hill	Hill	NNP	0
coefficient	coefficient	NN	0
.	.	.	0
For	For	IN	0
inhibition	inhibition	JJ	B-NP
experiment	experiment	NN	I-NP
,	,	,	0
cells	cells	NNS	0
were	were	VBD	0
exposed	exposed	VBN	0
to	to	TO	0
inhibitor	inhibitor	VB	0
alone	alone	RB	0
for	for	IN	0
30	30	CD	0
s	s	VBZ	0
prior	prior	RB	0
to	to	TO	0
co-exposure	co-exposure	JJ	B-NP
with	with	IN	0
5-HT	5-HT	CD	0
.	.	.	0
inhibited	inhibited	VBN	B-NP
response	response	NN	I-NP
were	were	VBD	0
calculated	calculated	VBN	0
as	as	IN	0
a	a	DT	0
fraction	fraction	NN	B-NP
of	of	IN	0
the	the	DT	0
response	response	NN	0
to	to	TO	0
5-HT	5-HT	CD	0
alone	alone	RB	0
.	.	.	0
Data	Data	NNP	0
were	were	VBD	0
plotted	plotted	VBN	0
as	as	IN	0
the	the	DT	0
fractional	fractional	JJ	0
response	response	NN	0
versus	versus	IN	0
the	the	DT	0
concentration	concentration	NN	0
of	of	IN	0
inhibitor	inhibitor	NN	0
and	and	CC	0
analysed	analysed	VBP	0
using	using	VBG	0
GraphPad	GraphPad	JJ	0
software	software	NN	0
.	.	.	0
The	The	DT	0
IC	IC	NNP	0
50	50	CD	0
value	value	NN	0
was	was	VBD	0
calculated	calculated	VBN	0
as	as	IN	0
the	the	DT	0
concentration	concentration	NN	0
of	of	IN	0
antagonist	antagonist	NNS	0
inhibiting	inhibiting	VBP	0
the	the	DT	0
5-HT	5-HT	JJ	0
evoked	evoked	JJ	0
response	response	NN	0
by	by	IN	0
50	50	CD	0
%	%	NN	0
.	.	.	0
A	A	DT	0
K	K	NNP	0
i	i	FW	0
value	value	NN	0
was	was	VBD	0
calculated	calculated	VBN	0
from	from	IN	0
the	the	DT	0
IC	IC	NNP	0
50	50	CD	0
using	using	VBG	0
the	the	DT	0
Cheng-Prusoff	Cheng-Prusoff	JJ	0
equation	equation	NN	0
.	.	.	0
Synthesis	Synthesis	NNP	0
of	of	IN	0
Lerisetron	Lerisetron	NNP	B-NP
and	and	CC	0
its	its	PRP$	0
analogs	analogs	NNS	0
All	All	DT	0
target	target	NN	B-NP
molecule	molecule	NN	I-NP
were	were	VBD	0
prepared	prepared	VBN	0
according	according	VBG	0
to	to	TO	0
a	a	DT	0
general	general	JJ	0
2-step	2-step	CD	0
synthesis	synthesis	NNS	0
reported	reported	VBD	0
previously	previously	RB	0
by	by	IN	0
orjale	orjale	NN	B-NP
et	et	FW	0
al	al	FW	0
.	.	FW	0
with	with	IN	0
only	only	RB	0
slight	slight	JJ	0
modification	modification	NN	B-NP
[	[	-LRB-	0
22	22	CD	0
23	23	CD	0
]	]	-RRB-	0
.	.	.	0
Commercially	Commercially	RB	0
available	available	JJ	0
2-chlorobenzimidazole	2-chlorobenzimidazole	NN	0
,	,	,	0
in	in	IN	0
dry	dry	JJ	0
DMF	DMF	NNP	B-NP
was	was	VBD	0
treated	treated	VBN	0
with	with	IN	0
a	a	DT	0
slight	slight	JJ	0
excess	excess	NN	0
of	of	IN	0
NaH	NaH	NNP	B-NP
,	,	,	0
(	(	-LRB-	0
1.1eq	1.1eq	NNP	0
)	)	-RRB-	0
.	.	.	0
After	After	IN	0
stirring	stirring	VBG	0
for	for	IN	0
1	1	CD	0
hour	hour	NN	0
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
,	,	,	0
one	one	CD	0
equivalent	equivalent	NN	0
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
alkyl	alkyl	JJ	B-NP
bromide	bromide	NN	I-NP
was	was	VBD	0
added	added	VBN	0
slowly	slowly	RB	0
and	and	CC	0
the	the	DT	0
reaction	reaction	NN	B-NP
mixture	mixture	VBZ	I-NP
heated	heated	VBN	0
under	under	IN	0
reflux	reflux	NN	B-NP
for	for	IN	0
>	>	CD	0
5	5	CD	0
hours	hours	NNS	0
(	(	-LRB-	0
the	the	DT	0
reaction	reaction	NN	0
was	was	VBD	0
monitored	monitored	VBN	0
by	by	IN	0
TLC	TLC	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
Reaction	Reaction	NN	B-NP
product	product	NN	I-NP
was	was	VBD	0
partitioned	partitioned	VBN	0
between	between	IN	0
water	water	NN	0
and	and	CC	0
methylene	methylene	JJ	B-NP
chloride	chloride	NN	I-NP
;	;	:	0
organic	organic	JJ	B-NP
layer	layer	NN	I-NP
was	was	VBD	0
dried	dried	VBN	0
(	(	-LRB-	0
Na	Na	NNP	0
2	2	CD	0
SO	SO	CD	0
4	4	CD	0
)	)	-RRB-	0
and	and	CC	0
concentrated	concentrated	VBN	0
in	in	IN	0
vacuum	vacuum	NN	B-NP
.	.	.	0
The	The	DT	0
solid	solid	JJ	0
residue	residue	NN	0
was	was	VBD	0
purified	purified	VBN	0
by	by	IN	0
Flash	Flash	NNP	B-NP
chromatography	chromatography	NN	I-NP
,	,	,	0
which	which	WDT	0
afforded	afforded	VBZ	0
the	the	DT	0
corresponding	corresponding	JJ	0
N-substituted	N-substituted	JJ	0
2-Chlorobenzimidazole	2-Chlorobenzimidazole	CD	0
intermediates	intermediates	NN	0
in	in	IN	0
good	good	JJ	0
yield	yield	NN	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
step	step	NN	I-NP
involved	involved	VBD	0
a	a	DT	0
nucleophilic	nucleophilic	JJ	B-NP
substitution	substitution	NN	I-NP
of	of	IN	0
the	the	DT	0
2-chloro	2-chloro	JJ	0
group	group	NN	0
by	by	IN	0
piperazine	piperazine	NN	B-NP
at	at	IN	0
high	high	JJ	0
temperatures	temperatures	NNS	0
.	.	.	0
The	The	DT	0
reaction	reaction	NN	0
was	was	VBD	0
performed	performed	VBN	0
neat	neat	JJ	0
using	using	VBG	0
4-10	4-10	RB	0
fold	fold	VB	0
excess	excess	JJ	0
piperazine	piperazine	NN	B-NP
and	and	CC	0
typically	typically	RB	0
heated	heated	VBN	0
for	for	IN	0
a	a	DT	0
short	short	JJ	0
period	period	NN	0
only	only	RB	0
,	,	,	0
(	(	-LRB-	0
30-45	30-45	FW	0
min	min	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
Similar	Similar	JJ	0
work-up	work-up	NN	0
afforded	afforded	VBN	0
a	a	DT	0
residue	residue	NN	0
that	that	WDT	0
was	was	VBD	0
purified	purified	VBN	0
by	by	IN	0
either	either	DT	0
crystallization	crystallization	NN	B-NP
or	or	CC	0
chromatography	chromatography	NN	B-NP
.	.	.	0
The	The	DT	0
yields	yields	NNS	0
ranged	ranged	VBD	0
from	from	IN	0
40-95	40-95	CD	0
%	%	NN	0
.	.	.	0
All	All	DT	0
compounds	compounds	NN	0
were	were	VBD	0
characterized	characterized	VBN	0
by	by	IN	0
NMR	NMR	NNP	B-NP
,	,	,	0
m	m	NN	B-NP
,	,	,	0
hrm	hrm	NN	B-NP
,	,	,	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
elemental	elemental	JJ	B-NP
analysis	analysis	NN	I-NP
or	or	CC	0
were	were	VBD	0
identical	identical	JJ	0
to	to	TO	0
literature	literature	VB	B-NP
report	report	NN	I-NP
.	.	.	0
Materials	Materials	NNPS	0
D-MEM	D-MEM	NNP	B-NP
,	,	,	0
Penicillin-Streptomycin	Penicillin-Streptomycin	NNP	B-NP
,	,	,	0
fetal	fetal	JJ	B-NP
bovine	bovine	JJ	I-NP
serum	serum	NN	I-NP
,	,	,	0
and	and	CC	0
Trypsin	Trypsin	NNP	B-NP
were	were	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
New	New	NNP	0
Life	Life	NNP	0
Technologies.	Technologies.	NNP	0
5-HT	5-HT	NNP	0
and	and	CC	0
MDL-72222	MDL-72222	NNP	B-NP
were	were	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
RBI.	RBI.	NNP	B-NP
[	[	-LRB-	0
3H	3H	NNP	0
]	]	-RRB-	0
-granisetron	-granisetron	NNP	0
(	(	-LRB-	0
84	84	CD	0
Ci	Ci	CD	B-NP
/	/	CD	I-NP
mmol	mmol	CD	I-NP
)	)	-RRB-	0
was	was	VBD	0
purchased	purchased	VBN	0
from	from	IN	0
New	New	NNP	0
England	England	NNP	0
Nuclear	Nuclear	NNP	B-NP
.	.	.	0
